

3.

Plaintiff Barbara Brown brings this action in her capacity as the Administrator of the Estate of Trévon Falson to recover all damages to which the Estate is entitled under Georgia law.

4.

Plaintiff Barbara Brown is the natural parent of Trévon Falson and brings this action for the wrongful death of her son, Trévon Falson.

5.

Defendant Emory Healthcare, Inc. is a legal entity existing under the laws of the State of Georgia. Said Defendant may be served through its registered agent for service, Amy Adelman, Emory University, 201 Dowman Drive, 312 Administrative Building, Atlanta, DeKalb County, Georgia 30322. When served with a copy of the Summons and Complaint in this matter, said Defendant will be subject to the jurisdiction of this Court.

6.

At all times material herein, Defendant Emory Healthcare, Inc. did maintain a principal office at 201 Dowman Drive NE, 102 Administrative Building, Atlanta, DeKalb County, Georgia 30322-1018.

7.

Defendants John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV are, upon information and belief, healthcare providers who are employees or agents of Defendant Emory Healthcare, Inc. who, while acting in said capacity, participated in the care and treatment of Trévon Falson at Emory University Hospital located in DeKalb County at all times relevant herein, and the identities of whom are unknown to Plaintiffs at this time.

8.

Defendant Emory University a/k/a Emory University Hospital is a legal entity existing under the laws of the State of Georgia. “Emory University Hospital” is a division of Defendant Emory University and is not a separate legal entity. Said Defendant may be served through its registered agent for service, Amy Adelman, Emory University, 201 Dowman Drive, 312 Administrative Building, Atlanta, DeKalb County, Georgia 30322. When served with a copy of the Summons and Complaint in this matter, said Defendant will be subject to the jurisdiction of this Court.

9.

At all times material herein, Defendant Emory University did maintain a principal office at 201 Dowman Drive, NE, 101 Administrative Building, Atlanta, DeKalb County, Georgia 30322-1018.

10.

Defendants John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV are, upon information and belief, healthcare providers who are employees or agents of Defendant Emory University who, while acting in said capacity, participated in the care and treatment of Trévon Falson at Emory University Hospital located in DeKalb County at all times relevant herein, and the identities of whom are unknown to Plaintiffs at this time.

11.

Defendant The Emory Clinic, Inc. is a legal entity existing under the laws of the State of Georgia. Said Defendant may be served through its registered agent for service, Amy Adelman, Emory University, 201 Dowman Drive, 312 Administrative Building, Atlanta, DeKalb County,

Georgia 30322. When served with a copy of the Summons and Complaint in this matter, said Defendant will be subject to the jurisdiction of this Court.

12.

At all times material herein, Defendant The Emory Clinic, Inc. did maintain a principal office at 1365 Clifton Road NE, Atlanta, DeKalb County, Georgia 30322-1013.

13.

Defendants John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV are, upon information and belief, healthcare providers who are employees or agents of Defendant The Emory Clinic, Inc. who, while acting in said capacity, participated in the care and treatment of Trévon Falson at Emory University Hospital located in DeKalb County at all times relevant herein, and the identities of whom are unknown to Plaintiffs at this time.

14.

Defendant Duc Q. Nguyen, M.D. is, upon information and belief, a resident of Tennessee and may be served at his residence located at 3910 Hobbs Road, Nashville, TN 37215. When served with a copy of the Summons and Complaint in this matter, said Defendant will be subject to the jurisdiction of this Court.

15.

At all times material herein, Defendant Duc Q. Nguyen, M.D. was an employee and/or agent of Defendant The Emory Clinic, Inc. and was acting in the course and scope of said capacity.

16.

At all times material herein, Defendant Duc Q. Nguyen, M.D. was an employee and/or agent of Defendant Emory Healthcare, Inc. and was acting in the course and scope of said capacity.

17.

At all times material herein, Defendant Duc Q. Nguyen, M.D. was an employee and/or agent of Defendant Emory University and was acting in the course and scope of said capacity.

FACTUAL ALLEGATIONS

18.

Trévon Falson was born on November 25, 1997.

19.

On or about June 14, 2016, Trévon presented to the emergency room at Midtown Medical Center in Columbus, Georgia, with symptoms of shortness of breath, nausea, epigastric pain, vomiting, coughing, and heart palpitations.

20.

At Midtown Medical Center, an echocardiogram was performed which showed severe left ventricular dysfunction and Trévon was diagnosed with congestive heart failure. He was transferred to Emory St. Joseph's Hospital of Atlanta on June 22, 2016 with a diagnosis of congestive heart failure.

21.

During his admission at Emory Saint Joseph's Hospital, Trévon Falson underwent surgery for implantation of a HeartWare left ventricular assist device (LVAD) on June 30, 2016, as a bridge to heart transplantation. The surgery to implant the LVAD was performed by Dr. Jeffrey S. Miller.

22.

A sternotomy was performed in order to access the heart and implant the LVAD.

23.

During the LVAD implantation, the outflow graft was wrapped in Gore-Tex, which was sutured around the outflow graft with 3-0 Prolene in a running suture. The pericardium was then reconstructed with a Gore-Tex patch.

24.

During his admission at Emory St. Joseph's Hospital of Atlanta, on July 1, 2016, a procedure was performed to insert a right impella implant to provide cardiac support. The right impella was explanted on July 18, 2016.

25.

Both the Emory St. Joseph's Hospital Advanced Heart Failure Team and the Emory University Hospital Advanced Heart Failure Team concurred that Trévon was a good candidate for heart transplantation. He was subsequently listed as a Status 1A Heart Transplant Candidate.

26.

On November 2, 2017, Trévon Falson was admitted to Emory University Hospital for heart transplantation. The primary surgeon for the procedure was Defendant Duc Q. Nguyen, M.D.

27.

Between the date of the LVAD implantation on June 30, 2016, and the heart transplantation on November 2, 2017, the named Defendants never performed a CT Scan of the thorax.

28.

A CT Scan of the thorax is mandatory for safe resternotomy as it demonstrates the proximity of the posterior plate of the sternum to the surface of the heart as well as the position of the LVAD driveline and outflow graft in relation to the sternum.

29.

The heart transplantation which began on November 2, 2017, was performed by Defendant Duc Q. Nguyen, M.D., and other agents and employees of Defendant Emory Healthcare, Inc., Defendant The Emory Clinic, Inc., and Defendant Emory University Hospital.

30.

After the LVAD implantation on June 30, 2016 and prior to the heart transplantation on November 2, 2017, neither Dr. Nguyen nor any of the other healthcare providers employed by the defendants ordered and/or adequately reviewed a CT Scan of the thorax.

31.

During the heart transplantation on November 2, 2017, a median re sternotomy was performed using a saw to enter the chest cavity.

32.

While performing the re sternotomy during the heart transplantation active bleeding was noted.

33.

Upon gaining access to the chest of Trévon Falson, it was determined that during the re sternotomy the outflow graft of the LVAD had been lacerated.

34.

As a result of this laceration, Trévon Falson suffered a massive bleed.

35.

A period of 40 minutes passed before the surgical team was able to gain control of the bleeding from the outflow graft, during which time Trévon Falson was hypotensive.

36.

Dr. Nguyen and the medical team proceeded with the transplant which was completed on November 3, 2017.

37.

After the transplantation surgery, Trévon Falson remained at Emory University Hospital in very critical condition until his death on December 25, 2017.

38.

Following implantation of the donor heart, Trévon was unable to be taken off of cardiopulmonary bypass.

39.

Trévon was placed on peripheral venoarterial ECMO support and was transferred to the ICU in very critical condition.

40.

Following the heart transplantation, there were times when Trévon was awake and able to communicate.

41.

He continued to have severe primary graft failure despite ECMO support with no evidence of recovery.

42.

Trévon eventually underwent a tracheostomy. He was diagnosed with acute renal failure and had acute liver injury with elevated bilirubin.

43.

Trévon was also diagnosed with multiple organ dysfunction and poor lung function.

44.

On December 24, 2017, Trévon showed signs of worsening clinical function and had increasing pressure and inotropic requirement despite BiVAD support. He subsequently developed asystole and the decision was made to turn off the Biventricular Assistive Device.

45.

Trévon died on December 25, 2017.

46.

The post-transplantation complications suffered by Trévon and his ultimate death were a direct result of the massive bleed caused by the laceration to the outflow graft during the transplant surgery on November 2, 2017.

COUNT I

47.

Plaintiffs incorporate by reference the allegations contained in paragraphs 1 through 46 as if fully set forth herein.

48.

At all times relative to the medical treatment rendered to Trévon Falson by Defendant Duc Q. Nguyen, M.D., on November 2, 2017, said Defendant had a duty to Trévon Falson to provide medical treatment within the standard of care normally exercised by physicians and healthcare professionals under like conditions and similar surrounding circumstances.

49.

On November 2, 2017, Defendant Duc Q. Nguyen, M.D. was negligent in his care and treatment of Trévon Falson and failed to comport with the requisite standard of care.

50.

Defendant Duc Q. Nguyen, M.D. deviated from the applicable the standard of care in that he failed to order and/or adequately review a CT Scan of the thorax prior to the heart transplantation on November 2, 2017, which would have disclosed the location of the outflow graft in relation to the posterior of the sternum.

51.

Defendant Duc Q. Nguyen, M.D. and the other operating room personnel failed to use the degree of care required in performing the resternotomy, which dictates a careful dissection of the sternum after locating the outflow graft by chest CT scan.

52.

The above-described acts and omissions of Defendant Duc Q. Nguyen, M.D. were contributing factors and proximate causes of the injuries suffered by Trévon Falson which ultimately led to his death.

53.

Attached hereto in accordance with O.C.G.A. § 9-11-9.1 is the Affidavit of Abbas Ardehali, MD, FACS, specifically setting forth at least one negligent act or omission claimed to exist and the basis for such claim against Defendant Duc Q. Nguyen, M.D.

54.

Defendant The Emory Clinic, Inc. is vicariously liability for the negligent acts and omissions of its agent and employee, Defendant Duc Q. Nguyen, M.D.

55.

Defendant Emory Healthcare, Inc. is vicariously liability for the negligent acts and omissions of its agent and employee, Defendant Duc Q. Nguyen, M.D.

56.

Defendant Emory University is vicariously liability for the negligent acts and omissions of its agent and employee, Defendant Duc Q. Nguyen, M.D.

COUNT II

57.

Plaintiffs incorporate by reference allegations contained in paragraphs 1 through 56 above as if fully set forth herein.

58.

At all times material herein, Defendant Emory Healthcare, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV had a duty to Trévon Falson to provide medical treatment within the standard of care normally exercised by physicians and healthcare providers under like conditions and similar surrounding circumstances.

59.

Defendant Emory Healthcare, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV were negligent in the care and treatment of Trévon Falson and failed to comport with the requisite standard of care.

60.

Defendant Emory Healthcare, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV deviated from the applicable standard of care in that they failed to perform and/or review a CT Scan of the thorax prior to the heart transplantation on November 2, 2017, which would have disclosed the location of the outflow graft in relation to the posterior of the sternum.

61.

Defendant Emory Healthcare, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV deviated from the applicable standard of care in that they failed to use the degree of care required in performing the resternotomy, which dictates a careful dissection of the sternum after locating the outflow graft by chest CT scan.

62.

The above-described acts and omissions of Defendant Emory Healthcare, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV were contributing factors and proximate causes of the injuries suffered by Trévon Falson which led to his death.

63.

Attached hereto in accordance with O.C.G.A. § 9-11-9.1 is the Affidavit of Abbas Ardehali, MD, FACS specifically setting forth at least one negligent act or omission claimed to exist in the basis for such claim against Defendant Emory Healthcare, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV.

64.

Defendant Emory Healthcare, Inc. is vicariously liable for the acts and omissions of its agents and employees, Defendant Duc Q. Nguyen, M.D. and John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV.

COUNT III

65.

Plaintiffs incorporate by reference allegations contained in paragraphs 1 through 64 above as if fully set forth herein.

66.

At all times material herein, Defendant Emory University and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV had a duty to Trévon Falson to provide medical treatment within the standard of care normally exercised by physicians and healthcare providers under like conditions and similar surrounding circumstances.

67.

Defendant Emory University and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV were negligent in the care and treatment of Trévon Falson and failed to comport with the requisite standard of care.

68.

Defendant Emory University and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV deviated from the applicable standard of care in that they failed to perform and/or review a CT Scan of the thorax prior to the heart transplantation on November 2, 2017, which would have disclosed the location of the outflow graft in relation to the posterior of the sternum.

69.

Defendant Emory University and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV deviated from the applicable standard of care in that they failed to use the degree of care required in performing the resternotomy, which dictates a careful dissection of the sternum after locating the outflow graft by chest CT scan.

70.

The above-described acts and omissions of Defendant Emory University and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV were

contributing factors and proximate causes of the injuries suffered by Trévon Falson which led to his death.

71.

Attached hereto in accordance with O.C.G.A. § 9-11-9.1 is the Affidavit of Abbas Ardehali, MD, FACS specifically setting forth at least one negligent act or omission claimed to exist in the basis for such claim against Defendant Emory University and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV.

72.

Defendant Emory University is vicariously liable for the acts and omissions of its agents and employees, Defendant Duc Q. Nguyen, M.D. and John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV.

COUNT IV

73.

Plaintiffs incorporate by reference allegations contained in paragraphs 1 through 72 above as if fully set forth herein.

74.

At all times material herein, Defendant The Emory Clinic, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV had a duty to Trévon Falson to provide medical treatment within the standard of care normally exercised by physicians and healthcare providers under like conditions and similar surrounding circumstances.

75.

Defendant The Emory Clinic, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV were negligent in the care and treatment of Trévon Falson and failed to comport with the requisite standard of care.

76.

Defendant The Emory Clinic, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV deviated from the applicable standard of care in that they failed to perform and/or review a CT Scan of the thorax prior to the heart transplantation on November 2, 2017, which would have disclosed the location of the outflow graft in relation to the posterior of the sternum.

77.

Defendant The Emory Clinic, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV deviated from the applicable standard of care in that they failed to use the degree of care required in performing the resternotomy, which dictates a careful dissection of the sternum after locating the outflow graft by chest CT scan.

78.

The above-described acts and omissions of Defendant The Emory Clinic, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV were contributing factors and proximate causes of the injuries suffered by Trévon Falson which led to his death.

79.

Attached hereto in accordance with O.C.G.A. § 9-11-9.1 is the Affidavit of Abbas Ardehali, MD, FACS specifically setting forth at least one negligent act or omission claimed to

exist in the basis for such claim against Defendant The Emory Clinic, Inc. and its agents and employees John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV.

80.

Defendant The Emory Clinic, Inc. is vicariously liable for the acts and omissions of its agents and employees, Defendant Duc Q. Nguyen, M.D. and John/Jane Doe I, John/Jane Doe II, John/Jane Doe III, and John/Jane Doe IV.


WHEREFORE, Plaintiffs pray as follows:

- a. That Summons be issued requiring the Defendants to plea or appear as required by law to answer this Complaint;
- b. That service be had upon the Defendants as provided by law;
- c. That a trial by jury be held;
- d. That Plaintiff Barbara Brown have and recover from Defendants in an amount in excess of \$10,000.00 to be proven at trial as damages for the full value of the life of Trévon Falson;
- e. That Plaintiff Barbara Brown have and recover from Defendants in an amount in excess of \$10,000.00 to be proven at trial as damages for the medical and healthcare related expenses incurred in the treatment and care of Trévon Falson;
- f. That Plaintiff Barbara Brown have and recover from the Defendants an amount to be proven at trial in excess of \$10,000.00 for the mental and physical pain and suffering of Trévon Falson;
- g. That Plaintiff Barbara Brown have and recover from the Defendants an amount to be proven at trial for the funeral expenses incurred for Trévon Falson;
- h. That all costs be cast against the Defendants; and

- i. That the Court award such other and further relief as the Court may deem just and proper.

This 19th day of November, 2018.

Respectfully submitted,



STEVEN R. WISEBRAM
Georgia Bar # 771350
LEE GUTSCHENRITTER
Georgia Bar # 831583

Attorneys for Plaintiffs

FINCH McCRANIE, LLP
225 Peachtree Street, NE
1700 South Tower
Atlanta, GA 30303
Phone - 404-658-9070
Fax – 404-688-0649
lee@finchmccranie.com
swisebram@finchmccraine.com

STATE COURT OF
DEKALB COUNTY, GA.
11/19/2018 4:09 PM
E-FILED
BY: Monica Gay

AFFIDAVIT OF ABBAS ARDEHALI, M.D.

STATE OF CALIFORNIA

COUNTY OF Los Angeles

Personally appeared before the undersigned officer duly authorized to administer oaths, Abbas Ardehali, MD, who after being duly sworn, deposes and states as follows:

1.

I am Abbas Ardehali, MD, a physician licensed to practice medicine in the State of California. I am over the age of 18 and otherwise competent to give this Affidavit.

2.

This Affidavit is based upon my personal knowledge, facts to which I am competent to testify, and my personal education, training, and experience. My curriculum vitae is attached as Exhibit A to this Affidavit.

3.

I graduated from Rutgers College in 1981 with a degree in Biochemistry and Biology, and then attended graduate school at Rutgers University, earning my M.S. in Chemical and Biochemical Engineering in 1982. After graduation from Rutgers, I attended Emory University School of Medicine, graduating magna cum laude in 1986. After obtaining my M.D. degree, I received a Masters in Public Health at the University of California, Berkeley in 1990.

4.

From 1986 – 1989, I was an intern and resident in Internal Medicine at the University of California, San Francisco, and a Fellow at the University of California, San Francisco Cardiovascular Research Institute from 1987-1989. Between 1990 and 1995, I was an Intern,

Resident, and Fellow in Surgery at the University of California, Los Angeles. From 1995 to 1997, I was a resident in Cardiothoracic Surgery at the University of California, Los Angeles.

5.

From 2006 until the present, I have been the Director of the Heart, Lung, and Heart-Lung Transplant Program at the UCLA Medical Center; and, from 1997 to the present I have been on the faculty at the David Geffen School of Medicine at UCLA, currently holding the appointments as Professor of Surgery and Professor of Medicine.

6.

I have presented numerous lectures in the area of cardiothoracic surgery including heart and lung transplantation, and have published approximately 145 peer reviewed articles in the area of cardiothoracic surgery, including heart and lung transplantation. In addition, I have written chapters for textbooks in the area of thoracic surgery pertaining to heart and lung transplantation and have served as Editor and Associate Editor of a textbook on cardiac surgery. The many manuscripts which I have prepared or presented in the area of cardiothoracic surgery, including heart and lung transplantation, are reflected in my CV which is attached as Exhibit A.

7.

I am certified by the American Board of Thoracic Surgery, The American Board of Surgery, the American Board of Internal Medicine, and I am a member of numerous professional society memberships and fellowships. Among the professional committee activities which are reflected on my CV, I am the Thoracic Committee Chair of the American Society of Transplant Surgeons and have held that position since 2014.

8.

From 1995 until the present, I have been actively involved in the practice of cardiothoracic surgery and involved in the practice of heart transplantation. Therefore, I have been actively involved in the practice of cardiothoracic surgery including heart transplantation, for at least 3 of the 5 years immediately preceding November 2, 2017.

9.

Based upon my education, training, and experience I am familiar with the standard of care required for surgeons performing resternotomies for explanting LVADs during heart transplant procedures.

10.

This Affidavit is also based upon the facts and information shown within the medical records from Emory Saint Joseph's Hospital in Atlanta, Georgia for the admission of Tre'von Falson beginning in June 22, 2016, and the hospital records from the Emory University Hospital for Tre'von Falson's admission beginning on November 2, 2017. Copies of these records are attached as Exhibit B.

11.

Based upon my review of the above-referenced records, I have found the following facts to have occurred and they are a factor and a basis upon which my opinions are founded:

a) On June 14, 2016, Tre'von Falson, 17 years old, presented to the Midtown Medical Center in Columbus, Georgia with symptoms of shortness of breath, nausea, epigastric pain, vomiting, coughing, and heart palpitations. He was diagnosed as suffering from congestive heart failure.

b) On June 22, 2016, Tre'von Falson was transferred from Midtown Medical Center in Columbus, Georgia to Emory Saint Joseph's Hospital in Atlanta, Georgia where he was admitted with a diagnosis of congestive heart failure.

c) During his admission at Emory Saint Joseph's Hospital, Tre'von Falson underwent surgery for implantation of a HeartWare left ventricular assist device (LVAD) on June 30, 2016, as a bridge to heart transplantation. The surgery to implant the LVAD was performed by Dr. Jeffrey S. Miller.

d) During the LVAD implantation, the outflow graft was wrapped in Gore-Tex, which was sutured around the outflow graft with 3-0 Prolene in a running suture. The pericardium was reconstructed with a Gore-Tex patch.

e) On July 1, 2016, during his admission at Emory Saint Joseph's Hospital, a procedure was performed to insert a right impella implant to provide cardiac support. The right impella implant was explanted on July 18, 2016.

f) Both the Emory Saint Joseph's Hospital Advanced Heart Failure Team and the Emory University Hospital Advanced Heart Failure Team concurred that Tre'von Falson was a good candidate for heart transplantation.

g) On November 2, 2017, Tre'von Falson was admitted to Emory University Hospital for heart transplantation. The primary surgeon for the procedure was Dr. Duc Nguyen.

h) While performing the re sternotomy during the heart transplantation active bleeding was noted.

i) Upon gaining access to the chest of Tre'von Falson, it was determined that during the re sternotomy the outflow graft of the LVAD had been lacerated.

j) As a result of this laceration, Tre'von Falson suffered a massive bleed.

k) A period of 40 minutes passed before the surgical team was able to gain control of the bleeding from the outflow graft, during which time Tre'von Falson was hypotensive.

l) Dr. Nguyen and the medical team proceeded with the transplant which was completed on November 3, 2017.

m) After the transplantation surgery, Tre'von Falson remained at Emory University Hospital in very critical condition until his death on December 25, 2017.

12.

It is my opinion within a reasonable degree of medical probability that the care Tre'von Falson received at the time of the heart transplantation performed by Dr. Nguyen and the other operating room personnel at Emory University Hospital did not comport with the standard of care required under these circumstances.

13.

The potential to damage the LVAD outflow graft during resternotomy is a known danger and should be prevented by the use of a chest CT scan and proper surgical technique.

14.

The standard of care for resternotomy under the conditions surrounding Tre'von Falson's transplantation requires that a chest CT scan, preferably with contrast, be performed prior to resternotomy to identify and determine the location of the outflow graft of the LVAD, and that the surgeon use extreme caution and proper technique in opening the chest.

15.

According to the records, neither Dr. Nguyen, nor any other healthcare provider employed by the defendants, ordered and/or adequately reviewed a chest CT scan for Tre'von Falson prior to the transplant surgery in order to identify and locate the position of the outflow graft.

16.

Furthermore, had Dr. Nguyen and the other operating room personnel used the degree of care required in performing the resternotomy, which dictates a careful dissection of the sternum after locating the outflow graft by chest CT scan, the damage to Tre'von Falson's outflow graft could have been avoided.

17.

It is my opinion, to a reasonable degree of medical probability, had Dr. Nguyen and the other healthcare providers employed by the defendants ordered and /or adequately reviewed a chest CT scan and used that degree of care required under the circumstances, the outflow graft would not have been lacerated and damaged during the surgery.

18.

Based upon my review of the records, it is my opinion, to a reasonable degree of medical probability, that the complications suffered by Tre'von Falson post-transplantation and his ultimate death were a direct result of the massive bleed caused by the laceration and damage to the outflow graft during the transplant surgery.

19.

This Affidavit is based on my training, my experience, personal knowledge, and upon my review of the aforementioned records and documents. It is not the purpose of this Affidavit to set forth each and every opinion or to include all criticisms that I may have now or may have in the future. I may have further opinions based upon review of additional records, other records which become available, and/or available information concerning the pertinent issues. The purpose of this Affidavit is to comply with O.C.G.A. § 9-11-9.1.

Further Affiant sayeth not.



ABBAS ARDEHALI, M.D.
Affiant

Sworn to and subscribed before me

This 27 day of Oct., 2018



Notary Public

Affix Seal:



CURRICULUM VITAE

Abbas Ardehali, M.D., F.A.C.S.

Current Position: Professor of Surgery
Division of Cardiac Surgery
William E. Conner Chair in Cardiothoracic Transplantation
Professor of Medicine, Division of Cardiology
David Geffen School of Medicine at UCLA
Director, UCLA Heart, Lung, and Heart-Lung Transplant Programs

Business Address: CHS 62-186
Center for Health Sciences
UCLA Medical Center
10833 Le Conte Ave
Los Angeles, CA 90095
Phone: (310) 825-5841
Fax: (310) 206-3506
Email: aardehali@mednet.ucla.edu

Home Address: 415 N. Bristol Avenue
Los Angeles, CA 90049

Personal: Married, 2 children

Citizenship: US

EDUCATION

College	Rutgers College, Rutgers University New Brunswick, NJ B.A. (Biochemistry and Biology) Cum Laude	1977-81
Graduate School	Rutgers University New Brunswick, NJ M.S. (Chemical and Biochemical Engineering)	1981-82
Medical School	Emory University School of Medicine Atlanta, GA M.D. Magna Cum Laude	1982-86
Graduate School	University of California, Berkeley Berkeley, CA M.P.H.	1988-90

Internship Internal Medicine	University of California, San Francisco San Francisco, CA	1986-87
Residency Internal Medicine	University of California, San Francisco San Francisco, CA	1987-89
Fellowship	University of California, San Francisco Cardiovascular Research Institute San Francisco, CA	1987-89
Internship Surgery	University of California, Los Angeles Los Angeles, CA	1990-91
Residency Surgery	University of California, Los Angeles Los Angeles, CA	1991-92
Fellowship Research	University of California, Los Angeles Los Angeles, CA	1992-93
Residency Surgery	University of California, Los Angeles Los Angeles, CA	1993-95
Residency Cardiothoracic Surgery	University of California, Los Angeles Los Angeles, CA	1995-97

CERTIFICATION

American Board of Thoracic Surgery	1998
American Board of Surgery	1996
American Board of Internal Medicine	1989

LICENSURE

California G62746	1988
-------------------	------

ACADEMIC APPOINTMENTS

Assistant Professor of Surgery David Geffen School of Medicine at UCLA	1997-03
Associate Professor of Surgery David Geffen School of Medicine at UCLA	2003-08

Professor of Surgery
David Geffen School of Medicine at UCLA 2008-present

Professor of Medicine
David Geffen School of Medicine at UCLA 2010-present

HOSPITAL APPOINTMENTS

Attending Cardiothoracic Surgeon
UCLA Medical Center 1997-present

Attending Cardiothoracic Surgeon
Greater Los Angeles VA Healthcare System 1997-2011

Attending Cardiothoracic Surgeon
Santa Monica-UCLA Medical Center 1997-2014

Chief, Division of Cardiac Surgery
Greater Los Angeles VA Healthcare System 1999-2011

Director, Lung Transplant Program
UCLA Medical Center 2000-present

Director, Heart, Lung and Heart-Lung Transplant Program
UCLA Medical Center 2006-present

PROFESSIONAL SOCIETY MEMBERSHIP AND FELLOWSHIPS

Society of University Surgeons 2010

American Association for Thoracic Surgery 2004

Western Thoracic Surgical Association 2002

American Society of Investigative Pathology 2002

Society of Thoracic Surgeons 2001

American Society of Transplant Surgeons 2001

American Society of Transplant Physicians 2001

American College of Surgeons 2000

ISHLT Annual Meeting.	1997
American College of Physicians	1988
American Institute of Chemical Engineering	1981

PROFESSIONAL COMMITTEES

American Society of Transplant Surgeons, Thoracic Committee Chair	2014-present
American Society of Transplant Surgeons, Thoracic Committee Co-chair	2011-2013
OPTN/UNOS Membership and Professional Standards Committee	2009-2011
American Society of Transplant Surgeons, Thoracic Committee	2008-2010
UNOS National Lung Review Board	2007-2008
Sherman M. Mellinkoff Faculty Award Search Committee, UCLA School of Medicine	2006-2008
Western Thoracic Surgical Association, Membership Committee	2005-2008
American Society of Transplant Surgeons, Thoracic Committee	2005-7
NIH Study Section-Special Emphasis Panel ZHL1-CSR-M	2004
UCLA Department of Surgery Executive Committee	2004-present
VA Merit Review Study Section-Surgery Committee B	2004-06
UCLA Transition Planning Committee	2003-05
American Society of Transplantation, Thoracic Transplantation Committee	2003-05
American Heart Association Study Section, Western States Affiliate Peer Review Committee	2002-05
United Network for Organ Sharing, Thoracic Committee	2002-05
United Network for Organ Sharing, Lung Allocation Committee	2002-05
American Society of Transplantation, Intra-Thoracic Committee	2002-05

UNOS, Region 5 Thoracic Review Board, Chairman	2002-05
American Society of Transplant Surgeons, Thoracic Committee	2002-03
UNOS, Region 5 Thoracic Review Board, Member	2000-02
Value Analysis Committee, UCLA Medical Center	1999-present
UCLA Division of Cardiothoracic Surgery Quality Assurance Committee Director	1998-present
UCLA Legislative Assembly of Academic Senate	1998-99
UCLA Surgical Education Committee	1998-2001
UCLA School of Medicine, Admission Committee	1998-2004

HONORS AND AWARDS

Ellis Island Medal of Honor	2017
Breath of Life Innovation Award, Cystic Fibrosis Foundation	2013
Castle Connolly Medical Ltd. Top Doctor	2011-present
Best Doctors in America	2007-present
Los Angeles & Southern California Super Doctors	2007-present
Guide to America's Top Surgeons	2010-13
Vitals Patient's Choice Award	2008-13
Scleroderma Foundation Spirit of Leadership Award, Los Angeles	2005
Second Alfred Blalock Research Scholarship Award The American Association for Thoracic Surgery	2000-02
Who's Who in America, 55 th Edition	2001
Who's Who in America, 55 th Edition	1999
Golden Apple Teaching Award UCLA School of Medicine Class of 1995	1995

Sandoz Pharmaceutical Award	1986
Alpha Omega Alpha	1985
Rutgers Graduate School Award	1981
Phi Beta Kappa	1980
Phi Sigma Iota (The Foreign Language National Honor Society, French)	1980

EDITORIAL ACTIVITIES

Editorial Board, Journal of Cardiovascular Pharmacology and Therapeutics	2006-2011
Editorial Board, Journal of Surgical Research	2002-07
Reviewer, Journal of Circulation Research	2006-present
Reviewer, Journal of Immunology	2002-present
Reviewer, Journal of Thoracic and Cardiovascular Surgery	2002-present
Reviewer, Circulation	2002-present
Reviewer, Journal of Heart and Lung Transplant	1997-present
Reviewer, Annals of Thoracic Surgery	1997-present

FUNDING

UC Center for Accelerated Innovations Award/ NIH Heart, Lung, and Blood Institute \$434,096	2015-17
Biom'Up, Inc \$280,593	2015-2016
OneLegacy, Inc \$40,750	2015-17
TransMedics, Inc.	2012

\$310,578	
TransMedics, Inc. \$241,316	2010
Marvin and Ann Browder Trust Fund \$1,000,000.00	2008
Holt and Ira Hickman Trust Fund \$500,000.00	2007
TransMedics, Inc. \$40,635.00	2007
American Heart Association, Established Investigator Award \$500,000.00	2005-09
Edwards Lifesciences, Inc. \$35,000.00	2006
Gayle Hoyt Lung Transplantation Research Fund \$100,000.00	2005
Paul and June A. Ebensteiner Trust Fund \$1,000,000.00	2002
VA Merit Grant \$333,900.00	2003-07
VA Cooperative Study #517 \$526,276.00	2002-07
Stein-Oppenheimer Foundation \$20,000.00	2002-03
Laubisch Foundation \$20,000.00	2001-02
American Heart Association, Scientist Development Grant \$280,000.00	2001-04
Second Alfred Blalock Research Scholarship Award, The American Association for Thoracic Surgery \$110,000.00	2000-02
Council on Research, Academic Senate	2000-01

\$1,900.00

Council on Research, Academic Senate
\$9,100.00

1998-99

INVITED LECTURES

Cutting Edge of Transplantation 02/18
American Society of Transplantation
Phoenix, AZ

Ex Vivo Heart Perfusion: Removing Time and Distance Barriers

Pulmonary Medicine Grand Rounds 11/17

David Geffen School of Medicine at UCLA
Los Angeles, CA

Ex Vivo Lung Perfusion for Lung Transplantation: Where are we going?

Cardiothoracic Surgery Grand Rounds 6/16

University of Alabama
Birmingham, AL

Future of Cardiothoracic Surgery

Optimal Therapies for end Stage Thoracic Organs Failure 5/16

American Association for Thoracic Surgery
Baltimore, MD

Ex Vivo Lung Perfusion for standard Lung Transplantation

UCLA Primary Care Conference-2016 4/16

Las Vegas, NV

Advances in Heart and Lung Transplantation

Cutting Edge of Transplantation – 2016 2/16

American Society of Transplantation
Phoenix, AZ

Ex Vivo Heart Perfusion and DCD Heart Donation

MHH International Symposium: Beyond Preservation – New Frontiers 1/16

in Warm Ex-vivo Perfusion of Thoracic Organs
Medizinische Hochschule Hannover

Hannover, Germany

The Future of Thoracic Donor Organ Perfusion

2015 American Transplant Congress 5/15

American Society of Transplant Surgeons
Philadelphia, PA

The Use of Extended Criteria Donor Hearts for Transplantation	
SCPMG Inaugural Transplant Symposium Kaiser Permanente Los Angeles, CA Use of Lung in a Box	2/15
Organ Banking Summit: "The Grand Challenges in Organ Preservation Organ Preservation Alliance Palo Alto & Stanford, CA While millions and millions of lives have been saved, organ transplantation still faces massive problems after 50 years; - Organ Preservation is a Big Part of the Solution	2/15
STS 51 st Annual Meeting The Society of Thoracic Surgeons San Diego, CA Warm, Ex Vivo Lung Preservation and Transport	1/15
3 rd Saudi Heart Failure Conference – Together We Overcome Failure Saudi HF – Saudi Heart Association Jeddah & Riyadh, Saudi Arabia Heart Transplantation, Demographics and Outcome LVAD Difficulties, Complications and Myocardial Recovery Heart & Lung Transplant at UCLA	12/14
Frontiers in Organ Failure and Transplant Management Houston Methodist J.C. Walter Jr. Transplant Center Houston, TX The Future and Ex Vivo Thoracic Organ Perfusion	12/14
8 th Annual Earl Bakken Symposium 2014: Advances in Heart & Lung Transplantation University of Minnesota Minneapolis, MN Normothermic Beating Heart Preservation PROCEED II and EXPAND trials	12/14
Advances in Lung Transplantation & Pulmonary Arterial Hypertension 2014 UCLA Los Angeles, CA Aging of Lung Transplant Recipients Cardiac Repair: Strategies Concurrent with Lung Transplant	11/14
Lori Thompson Leist Visiting Professorship	10/14

Mayo School of Continuous Professional Development Jacksonville, FL Ex-vivo Lung Perfusion	
The 19 th Annual Scientific & Cultural Meeting The Academy of Persian Physicians San Diego, CA Heart Transplantation: The Present and the Future	9/14
2014 HFSA Annual Scientific Meeting Heart Failure Society of America Las Vegas, NV New Strategies in Organ Preservation: An Update on PROCEED II	9/14
2014 Thoratec Symposium Thoratec Corporation Tehran, Iran VAD Technology	6/14
2014 ISHLT Annual Meeting & Scientific Sessions The International Society for Heart & Lung Transplantation San Diego, CA Ex-vivo Donor Heart Perfusion for Heart Transplantation: The PROCEED Trial & Update on the International, Randomized PROCEED II Trial Comparing Standard Cold Preservation Against Physiological Perfusion With Transmedics Cardiac OCS	4/14
TransMedics OCS Lung Symposium TransMedics, Inc. Venice, Italy USA Experience with OCS Lung & The Future of Lung Transplantation	2/14
STS 50 th Annual Meeting & STS/AATS Tech-Con 2014 Society of Thoracic Surgeons & American Association for Thoracic Surgery Orlando, FL Ex-Vivo Heart Perfusion Circuits	1/14
2013 Cardiothoracic Transplant Patient Education Symposium UCLA Heart & Lung Transplant Programs Los Angeles, CA UCLA Heart & Lung Transplant Programs	11/13
UCLA Department of Medicine Pathology & Lab Grand Rounds UCLA Los Angeles, CA Lung Transplantation: The Science and The Art.	11/13

6 th International Congress on Pulmonary Diseases, Intensive Care & Tuberculosis National Research Institute of Tuberculosis and Lung Diseases Tehran, Iran Organ Care System: INSPIRE Trial	10/13
16 th ESOT Congress 2013 European Society for Organ Transplantation Vienna, Austria Heart preservation: Results of PROCEED II Clinical Trial	9/13
2013 National Donor Management Summit Organ Donation & Transplantation Alliance Los Angeles, California Out of Body Experiences	9/13
UCLA Heart Failure Symposium 2013 UCLA Los Angeles, CA UCLA Heart Transplantation: 2013	5/13
4 th Annual UCLA Donation & Transplantation Symposium UCLA Los Angeles, CA Lung in a Box.	4/13
Kaiser Annual Mid-Winter Conference 2013 Kaiser Permanente Vail, Colorado Treatments of End-stage Lung Diseases	2/13
25 th Journees de la Pitie Institut e Cardiologie Paris, France Ex-vivo Thoracic Grafts Rehabilitation - European Results	10/12
Kaiser 2012 Annual Interdisciplinary Winter Conference Kaiser Permanente Lake Tahoe, CA Surgical Management of Heart Failure	2/12
2011 ISHLT Annual Meeting & Scientific Sessions The International Society for Heart & Lung Transplantation San Diego, CA Cardiopulmonary Bypass Strategies for Double Lung Transplant:	4/11

UCLA Experience

TransMedics Scientific Symposium, 2011 ISHLT TransMedics, Inc. San Diego, CA Long Term Clinical Value of OCS HEART and Initial Clinical Experience with OCS LUNG	4/11
UCLA Cardiology Update II UCLA Santa Barbara, CA Surgical Management of Heart Failure	2/11
UCLA Cardiology Update I UCLA Anaheim, CA Surgical Management of Heart Failure	1/11
The 14th Annual UCLA Primary Care Update 2010 UCLA Las Vegas, NV Meeting the Clinical Challenge	10/10
The 15 th Annual Scientific & Cultural Meeting The Academy of Persian Physicians San Diego, CA Art and Science of Lung Transplantation	10/10
The 24 th Annual IMS CME Symposium UCLA Los Angeles, CA Advances in Cardiac Surgery	3/10
UCLA Department of Medicine Grand Rounds UCLA Los Angeles, CA Heart Failure: Surgical Options	2/09
WLA VA Annual Medical Staff Meeting VA Greater Los Angeles Healthcare System Los Angeles, CA Cardiac Surgery: Present and Future	1/09
Division of Cardiothoracic Surgery University of Nebraska University of Nebraska Omaha, NE	4/08

Advances in Surgical Treatment of Heart Failure	
WLA VA Department of Medicine Grand Rounds VA Greater Los Angeles Healthcare System Los Angeles, CA Surgical Treatment of End-Stage Heart Disease	4/08
28 th ISHLT Annual Meeting & Scientific Sessions The International Society for Heart & Lung Transplantation Boston, MA Ex-vivo Assessment of the Donor Heart: New Opportunities	4/08
ASTS State of the Art Winter Symposium American Society of Transplant Surgeons Marco Island, FL Under Pressure: Pulmonary Hypertension in Heart Transplant Recipients	1/08
UCLA Division of Cardiology Grand Rounds UCLA Los Angeles, CA Surgical Treatment of End-Stage Heart Disease	1/08
UCLA Heart Failure/Transplant Symposium UCLA Santa Monica, CA Surgical Advances in Patients with High Risk CAD and CHF	10/07
UCLA Department of Surgery Grand Rounds UCLA Los Angeles, CA Lung Transplantation: Current State of Affairs	2/07
World Transplant Congress ASTS, TTS, AST Boston, MA Role of Chemokines in Chronic Allograft Rejection	7/06
UCLA Department of Medicine Grand Rounds UCLA Los Angeles, CA Lung Transplantation: The Science and the Art	5/06
6th Annual ASTS Winter Symposium American Society of Transplant Surgeons Scottsdale, AZ Graft Loss: Predictive Factors & Preventive Strategies, Alternative Hearts	1/06

Expert Advisory Panel Chicago, IL Chairman, Inhaled Carbon Monoxide in Lung Transplantation	10/05
WTSA 31 st Annual Meeting Western Thoracic Surgical Association Victoria, British Columbia Invited Discussant: Ischemia Inducible Gene Therapy for Myocardial Infarction	6/05
URN 6th Annual Symposium: Emerging Technologies and Innovative Approaches for Managing Patients with Complex Medical Problems Scottsdale, AZ Lung Transplantation: The New Allocation System and Optimal Timing	4/05
Global Expert Advisory Panel INO Therapeutics San Juan, Puerto Rico Inhaled Vasodilator Therapy in Pulmonary Hypertension.	3/05
Health Learning System Wayne, NJ Vasoactive Substances as Diagnostic Tools in Cardiorespiratory Pathology Roundtable	11/04
72nd Annual AHA Fall Symposium American Heart Association Los Angeles, CA Mitral Valve Repair	10/04
Tanabe Research Laboratories San Diego, CA Chemokines in Solid Organ Transplantation	9/04
Adult Cardiac Nitric Oxide Consensus Conference Short Hills, NJ Nitric Oxide in Thoracic Transplantation	4/04
Cardiovascular Collaborative Symposium Providence Health Systems Burbank, CA What's on Horizon in Surgical Treatment of Congestive Heart Failure?	11/03
Recent Insights and New Perspectives in Lung Transplantation University of Pavia	10/03

Pavia, Italy Modified Reperfusion in Non-Standard Lungs	
2003 American Transplant Congress American Society of Transplant Surgeons Washington, DC Complications of Heart Transplantation.	5/03
AATS 2003 Annual Meeting American Association for Transplant Congress Washington, DC Re-evaluating the Patients on the Waiting List	5/03
American Association for Thoracic Surgery Annual Meeting Boston, MA Second Alfred Blalock Research Scholarship Lecture	5/03
UCLA Division of Cardiothoracic Surgery Grand Rounds UCLA Los Angeles, CA Lung Transplantation: Challenges and Advances	12/02
UCLA Cardiology Update Symposium 2002 UCLA Santa Monica, CA Update on Cardiovascular Surgery in 2002	8/02
UCLA Pulmonary and Critical Care Update UCLA Marina Del Rey, CA Expanding the Donor Pool for Lung Transplantation	7/02
Regional Department of Cardiac Surgery Kaiser-Permanente Medical Center Los Angeles, CA Lung Transplantation: Advances and Challenges	2/02
2 nd Annual ASTS Winter Symposium American Society of Transplant Surgeons Miami Beach, FL IRI: Achilles Heel of Lung Transplantation	1/02
UCLA Symposium on New Frontiers in the Management of Cardiopulmonary Diseases UCLA Las Vegas, NV	4/01

Advances in Cardiothoracic Surgical Management of End-stage Heart and Lung Disease.	
Department of Surgery Grand Rounds Martin Luther King Medical Center Los Angeles, CA Advances in Human Lung Transplantation	3/01
Division of Cardiology Grand Rounds UCLA Los Angeles, CA Surgical Treatment of LV Aneurysms and Post-Infarct VSD	6/00
Medicine Grand Rounds Tarzana-Encino Health Care System Tarzana, CA Surgical Treatment of Heart Failure	2/00
Division of Cardiology Grand Rounds UCLA Los Angeles, CA Gene Therapy and Heart Transplantation	11/99
Department of Surgery Grand Rounds Harbor-UCLA Los Angeles, CA Complete Myocardial Revascularization on a Beating Heart	3/99
Division of Cardiothoracic Surgery Grand Rounds UCLA Los Angeles Inhaled Nitric Oxide and Thoracic Transplantation.	10/98
Western Regional Meeting Medtronic Santa Barbara, CA Comparison of Myocardial Stabilization Systems for Off-pump Coronary Bypass Surgery	6/98
Tehran Heart Institute Grand Rounds Tehran Heart Institute Tehran, Iran Ischemic Cardiomyopathy: Surgical Options.	9/97
Department of Medicine Grand Rounds Kaiser Permanente Medical Center	7/97

Los Angeles, CA Surgical Treatment of Ischemic Cardiomyopathy.	
Department of Surgery Grand Rounds, UCLA UCLA Los Angeles, CA Cardiac Allograft Vasculopathy in Mice and Humans.	5/93
UCLA Division of Cardiothoracic Surgery Grand Rounds UCLA Los Angeles, CA The Impact of Cold Storage of Cardiac Allografts on Expression of MHC Antigens and Vascular Adhesion Molecules.	2/93
UCLA Division of Cardiothoracic Surgery Grand Rounds UCLA Los Angeles, CA Hyperacute Rejection of Cardiac Allografts.	8/92
Georgia Nutrition Council Atlanta, GA Dietary Requirements of Patients with Cirrhosis.	3/84

OTHER ACADEMIC ACTIVITIES

Patent: Left Ventricular Decompression Catheter Device International Patent Application No: PENDING U.S. Provisional Application No. 62/585,712, filed November 14, 2017	2017
Patent: Dual Lumen Catheter for Lung Assist Device International Patent Application No. PCT/US15/27334, filed April 23, 2015 U.S. Provisional Patent Application No. 61/983,804, filed April 24, 2014	2014
Principle Investigator, UCLA Prospective, International, Multi-center, Randomized Clinical Investigation of TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation (INSPIRE)	2012-14
Clinical Advisory Board Paragonix Technologies, Inc.	2012
Chair, Steering Committee Prospective, Multi-center, Safety and Effectiveness Evaluation of the Organ Care System Device for Cardiac Use (PROCEED II)	2009-13

Lecturer, Department of Pathology and Laboratory Medicine, Pathology 240	2004-present
Abstract Review Committee Member, International Society of Heart & Lung Transplantation Annual Meeting	2002-present
Chair, Abstract Review Committee; Clinical (Heart). American Transplant Congress, Boston, MA	2005
Moderator, Advances in Cardiac Surgery, 72nd Annual AHA Fall Symposium, Los Angeles, CA	2004
Chair, Abstract Review Committee; Clinical (Heart). American Transplant Congress, Seattle, WA	2004
Program Committee Member, International Society of Heart & Lung Transplantation Annual Meeting, San Francisco, CA	2004
Chair, Abstract Review Committee; Clinical (Heart). American Transplant Congress, Washington, DC	2003
Organizing Committee Member, ASTS Winter Symposium. Ischemia-Reperfusion Injury: From Bench to Bedside, Miami Beach, FL	2002
Committee Member for the PhD Degree in Pathology and Laboratory Medicine, UCLA School of Medicine, Candidate: James Yun, MD	2001
Committee Member for the PhD Degree in Microbiology and Immunology, UCLA School of Medicine, Candidate: Michael Peter Fischbein, MD	2000

MANUSCRIPTS

1. Hamadeh R, Ardehali A, Locksley RM, York MK: Fatal aspergillosis in a marrow transplant recipient associated with smoking contaminated marijuana, in a marrow transplant recipient. *Chest*. 1988;94(2):432-3.
2. Tribble DL, Jones DP, Ardehali A, Feeley RM, Rudman D. Hypercysteinemia and delayed sulfur excretion in cirrhotics after oral cysteine loads. *Am J Clin Nutr*. 1989;50(6):1401-6.
3. Ardehali A, Ports TA. Myocardial oxygen supply and demand. *Chest*. 1990; 98(3):669-705.
4. Ardehali A. Comparison of indications for aortic valve replacement in 1978 and in 1988. *Am J Cardiol*. 1990;66(12):1016-8.

5. Ardehali A, Billingsley A, Laks H, Drinkwater DC, Sorensen TJ, Drake TA. Experimental cardiac allograft vasculopathy in mice. *J Heart Lung Transplant.* 1993;12(5):730-5.
6. Laks H, Gates RN, Ardehali A, Capouya ER, Moriguchi JD, Kobashigawa JA, Stevenson LW. Orthotopic heart transplantation and concurrent coronary bypass. *J Heart Lung Transplant.* 1993;12(5):810-5.
7. Ardehali A, Laks H, Drinkwater DC, Ziv ET, Sorensen TJ, Hamilton MA, Stevenson LW, Moriguchi JB, Kobashigawa JA. Cardiac transplantation at UCLA. *Clinical Transpl.* 1993:119-27.
8. Ardehali A, Laks H, Drinkwater DC Jr, Kato NS, Perrnut LC, Grant PW, Aharon AS, Drake TA. Expression of major histocompatibility antigens and vascular adhesion molecules on human cardiac allografts preserved in University of Wisconsin solution. *J Heart Lung Transplant.* 1993;12:1044-52.
9. Ardehali A, Drinkwater DC Jr, Laks H, Drake TA. Cardiac allograft vasculopathy. *Am Heart J.* 1993;126(6):1498-502.
10. Aharon AS, Laks H, Drinkwater DC, Chugh R, Gates RN, Grant PW, Permut LC, Ardehali A, Rudis E. Early and late results of mitral valve repair in children. *J Thorac Cardiovasc Surg.* 1994;07(5):1262-71.
11. Ardehali A, Laks H, Drinkwater DC, Kobashigawa J, Moriguchi J, Drake TA. Vascular Cell Adhesion Molecule-1 upregulation precedes and predicts cellular rejection of human cardiac-allografts. *Surg Forum.* 1995;92(3):450-6.
12. Drinkwater DC, Rudis E, Laks H, Ziv E, Marino J, Stein D, Ardehali A, Aharon A, Moriguchi J, Kobashigawa J. University of Wisconsin solution versus Stanford cardioplegic solution and the development of cardiac allograft vasculopathy. *J Heart Lung Transplant.* 1995;14(5):891-6.
13. Laks H, Ardehali A, Grant PW, Allada V. Aortic reimplantation of anomalous left coronary artery: An improved surgical approach. *J Thorac Cardiovasc Surg.* 1995;109(3):519-23.
14. Ardehali A, Fyfe A, Laks H, Drinkwater DC Jr, Qiao JH, Lysis AJ. Direct gene transfer into donor hearts at the time of harvest. *J Thorac Cardiovasc Surg.* 1995;109(4):716-20.
15. Ardehali A, Gates RN, Laks H, Drinkwater DC Jr, Rudis E, Sorensen TJ, Chang P, Aharon A. The regional capillary distribution of retrograde blood cardioplegia in explanted human hearts. *J Thorac Cardiovasc Surg.* 1995;109(5):935-40.

16. Rudis E, Gates RN, Laks H, Drinkwater DC, Ardehali A, Aharon A, Chang P. Coronary sinus ostial occlusion during retrograde cardioplegic distribution and efficacy. *J Thorac Cardiovasc Surg.* 1995;109(5):941-7.
17. Laks H, Ardehali A, Grant PW, Permut L, Aharon A, Kuhn M, Isabel-Jones J, Galindo A. Modification of the Fontan Procedure: Superior vena cave to left pulmonary artery connection and inferior vena cave to right pulmonary artery connection with adjustable atrial septal defect. *Circulation.* 1995;91(12):2943-2947.
18. Ardehali A, Segal J, Cheitlin MD. Coronary blood flow reserve in acute aortic regurgitation. *J Am Coll Cardiol.* 1995;25(6):1387-92.
19. Ardehali, A. Heart Transplantation: accelerated graft atherosclerosis. *Adv Card Surg.* 1995;6:195-205.
20. Ardehali A, Laks H, Drinkwater DC, Ziv E, Drake TA. Vascular cell adhesion molecule-1 is induced on vascular endothelia and medial smooth muscle cells in experimental cardiac allograft vasculopathy. *Circulation.* 1995;92(3):450-6.
21. Ardehali A, Laks H, Drinkwater DC, Gates RN, Kaczer E. Ventricular effluent of retrograde cardioplegia in human hearts has traversed capillary beds. *Ann Thorac Surg.* 1995;60(1):78-83.
22. Gates RN, Laks H, Drinkwater DC, Ardehali A, Aharon AS, Zaragoza AM, Chang PA. Can improved microvascular perfusion be achieved by using both antegrade and retrograde cardioplegia? *Ann Thorac Surg.* 1995;60(5):1308-11.
23. Drinkwater DC, Rudis E, Laks H, Ziv E, Marino J, Stein D, Ardehali A, Aharon A, Moriguchi J, Kobashigawa J. University of Wisconsin solution versus Stanford cardioplegic solution and the development of cardiac allograft vasculopathy. *J Heart Lung Transplant.* 1995;14(5):891-6.
24. Fyfe AI, Ardehali A, Laks H, Drinkwater DC, Lusic AJ. Biologic modification of the immune response in mouse cardiac isografts using gene transfer. *J Heart Lung Transplant.* 1995;14:S165-70.
25. Ardehali A, Segal J, Cheitlin MD. An improved valve-spreading catheter for producing reversible graded acute aortic insufficiency. *Cardiology.* 1996;87(4):276-8.
26. Lee J, Gates RN, Drinkwater DC, Rhudis E, Aharon A, Ardehali A, Chang P. A comparison of distribution between simultaneously or sequentially delivered antegrade/retrograde blood cardioplegia. *J Card Surg.* 1996;11(2):111-5.

27. Ardehali A, Laks H, Allada V. Management of the anomalous origin of the left coronary artery from the pulmonary artery. *Adv Card Surg.* 1996;7:137-46.
28. Lee JR, Laks H, Drinkwater DC, Blitz A, Lam L, Shiraishi Y, Chang P, Drake TA, Ardehali A. Cardiac gene transfer by intracoronary infusion of adenovirus vector-mediated reporter gene in the transplanted mouse heart. *J Thorac Cardiovasc Surg.* 1996;111(1):246-52.
29. Marelli D, Laks H, Amsel B, Jett GK, Couper G, Ardehali A, Galindo A, Drinkwater DC. Temporary mechanical support with BVS 5000 assist device during treatment of acute myocarditis. *J Card Surg.* 1997;12(1):55-9.
30. Ardehali A, Kessler D, Foroushani F, Laks H. Multivessel coronary artery bypass surgery without cardiopulmonary bypass. *Am Heart J.* 1999;138(5 Pt 1):983-6.
31. Ardehali A, Reddy R, Laks H. Gene therapy and heart transplantation. *Expert Opin Investig Drugs.* 2000;9(5):1021-7.
32. Yun J, Fischbein MP, Laks H, Fishbein MC, Espejo ML, Ebrahimi K, Irie Y, Berliner JA, Ardehali A. Early and late chemokine production correlates with cellular recruitment in cardiac allograft vasculopathy. *Transplantation.* 2000;69(12):2515-24.
33. Fischbein MP, Ardehali A, Yun J, Schoenberger S, Laks H, Irie Y, Dempsey P, Cheng G, Fishbein MC, Bonavida B. CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants. *J Immunol.* 2000;165(12):7316-22.
34. Marelli D, Laks H, Bresson J, Houston E, Fazio D, Tsai FC, Hamilton M, Moriguchi J, Fonarow GC, Ardehali A, Camara R, Burch C, Alejos JC, George B, Kawata N, Kobashigawa J. Sixteen-year experience with 1,000 heart transplants at UCLA. *Clin Transpl.* 2000:297-310.
35. Fischbein MP, Yun J, Laks H, Fishbein MC, Irie Y, Wortham C, Bonavida B, Ardehali. CD8+ lymphocytes participate in the development of chronic rejection. *J Heart Lung Transplant.* 2001;20(2):228-229.
36. Marelli D, Tsai F, Laks H, Houston E, Bresson J, Friend L, Gjertson D, Sykes A, Ardehali A, Esmailian F, Hamilton M, Fonarow G, Moriguchi J, Plunkett M, Hage A, Brown M, Mark M, Kobashigawa J. Use of hearts transplanted from donors with atraumatic intracranial bleeds. *J Heart Lung Transplant.* 2001;20(2):256.
37. Yun JJ, Fischbein MP, Laks H, Fishbein MC, Irie Y, Strieter R, Berliner JA, Ardehali A. Sustained production of the chemokine MIG precedes intimal thickening in chronic rejection. *J Heart Lung Transplant.* 2001;20(2):156.

38. Ross DJ, Chan RC, Kubak B, Ardehali A, Laks H, Nichols WE. Bronchiolitis obliterans with organizing pneumonia: possible association with human herpes virus- 7 infection after lung transplantation. *J Heart Lung Transplant.* 2001;20(2):171.
39. Yun JJ, Fischbein MP, Laks H, Fishbein M, Irie Y, Espejo M, Berliner JA, Ardelai A. Sustained rantes production is necessary for CAV development. *J Heart Lung Transplant.* 2001;20(2):185.
40. Fischbein MP, Yun J, Laks H, Irie Y, Fishbein MC, Espejo M, Bonavida B, Ardehali A. CD8+ lymphocytes augment chronic rejection in a MHC class II mismatched model. *Transplantation.* 2001;71(8):1146-53.
41. Ardehali A, Laks H, Levine M, Shpiner R, Ross D, Watson LD, Shvartz O, Sangwan S, Waters PF. A prospective trial of Inhaled Nitric Oxide in clinical lung transplantation. *Transplantation.* 2001;72(1):112-5.
42. Yun JJ, Fischbein MP, Laks H, Irie Y, Espejo ML, Fischbein MC, Berliner JA, Ardehali A. RANTES production during development of Cardiac Allograft Vasculopathy. *Transplantation.* 2001;71(11):1649-56.
43. Ardehali A, Hughes K, Sadeghi A, Esmailian A, Marelli D, Moriguchi J, Hamilton MA, Kobashigawa J, Laks H. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. *Transplantation.* 2001;72(4):638-41.
44. Fischbein MP, Yun J, Laks H, Irie Y, Fishbein MC, Bonavida B, Ardehali A. Role of CD8 lymphocytes in chronic rejection of transplanted hearts. *J Thorac Cardiovasc Surg.* 2002;123(4):803-9.
45. Ardehali A, Fischbein MP, Yun J, Irie Y, Fishbein MC, Laks H. Indirect alloreactivity and chronic rejection. *Transplantation.* 2002;73(11):1805-7.
46. Fairhurst RM, Kubak BM, Shpiner RB, Levine MS, Pegues DA, Ardehali A. Mycobacterium abscessus empyema in a lung transplant recipient. *J Heart Lung Transplant.* 2002;21(3):391-4.
47. Tsai FC, Marelli D, Bresson J, Gjertson D, Kermani R, Ardehali A, Esmailian F, Hamilton M, Fonarow GC, Moriguchi J, Plunkett M, Hage A, Tran J, Kobashigawa JA, Laks H. Recent trends in early outcome of adult patients after heart transplantation. *Am J Transplant.* 2002;2(6):539-45.
48. Tsai FC, Marelli D, Laks H, Moriguchi J, Sopher M, Bresson J, Moghaddam S, Kubak B, Esmailian F, Ardehali A, Plunkett M, Litwin I, Kobashigawa J. Short-term bridge to heart transplant using the BVS 5000 external ventricular assist device. *Am J Transplant.* 2002;2(7):646-51.

49. Yun JJ, Fischbein MP, Whiting D, Irie Y, Fishbein MC, Burdick MD, Belperio J, Strieter RM, Laks H, Berliner J, Ardehali A. The role of MIG/CXCL-9 in cardiac allograft vasculopathy. *Am J Pathol.* 2002;161(4):1307-13.
50. Marelli D, Laks H, Kobashigawa JA, Bresson J, Ardehali A, Esmailian F, Plunkett M, Kubak B. Seventeen-year experience with 1,083 heart transplants at a single institution. *Ann Thorac Surg.* 2002;74:1558-67.
51. Kao J, Moriguchi J, Ardehali A, Shannon K, Boyle N. Use of a donor heart with symptomatic WPW in an alternate donor program. *J Heart Lung Transplant.* 2002;21(12):1310-3.
52. Laks H, Marelli D, Fonarow G, Hamilton M, Ardehali A, Moriguchi J, Bresson J, Gjertson D, Kobashigawa J. Use of two recipient lists for adults requiring heart transplantation. *J Thorac Cardiovasc Surg.* 2003;125:49-59.
53. Fischbein MP, Yun J, Laks H, Irie Y, Oslund-Pinderski L, Fishbein MC, Bonavida B, Ardehali A. Regulated IL-10 expression prevents chronic rejection of transplanted hearts. *J Thorac Cardiovasc Surg.* 2003;126(1):216-23.
54. Marelli D, Laks H, Bresson S, Ardehali A, Bresson J, Esmailian F, Plunkett M, Moriguchi J, Kobashigawa J. Results after transplantation using donor hearts with preexisting coronary artery disease. *J Thorac Cardiovasc Surg.* 2003;126(3):821-5.
55. Whiting D, Banerji A, Ross D, Levine M, Shpiner R, Lackey S, Ardehali A. Liberalization of donor criteria in lung transplantation. *Am Surg.* 2003;69(10):909-12.
56. Belperio JA, Keane MP, Burdick MD, Lynch JP 3rd, Zisman DA, Xue YY, Li K, Ardehali A, Ross DJ, Strieter RM. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. *J Immunol.* 2003;171(9):4844-52.
57. Ardehali A, Laks H, Russell H, Levine M, Shpiner R, Lackey S, Ross D. Modified reperfusion and ischemia-reperfusion injury in human lung transplantation. *J Thorac Cardiovasc Surg.* 2003;126(6):1929-34.
58. Whiting D, Banerji a, Ross D, Levine M, Shpiner R, Lackey S, Ardehali A. Liberalization of donor criteria for lung transplantation. *Am Surg.* 2003;69(10):909-12.
59. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odum J, Laks H, Sen L. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. *Circulation.* 2004;109(3):363-8.

60. Yun JJ, Whiting D, Fischbein MP, Banerji A, Irie Y, Stein D, Fishbein MC, Proudfoot AEI, Laks H, Berliner J, and Ardehali A. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. *Circulation*. 2004;109(7):932-7.
61. Whiting D, Hsieh G, Yun JJ, Banerji A, Yao W, Fishbein MC, Belperio J, Streiter RM, Bonavida B, Ardehali A. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T-lymphocyte proliferation and effector cytokine production. *J Immunol*. 2004;172(12):7417-24.
62. Schnickel GT, Whiting D, Hsieh G, Yun JJ, Fischbein MP, Fishbein MC, Yao W, Shafizadeh A, Ardehali A. CD8 Lymphocytes are sufficient for the development of chronic rejection. *Transplantation*. 2004;78(11):1634-1639.
63. Ross DJ, Cole AM, Yoshioka D, Park AK, Belperio JA, Laks H, Strieter RM, Lynch JP 3rd, Kubak B, Ardehali A, Ganz T. Increased bronchoalveolar lavage human beta-defensin type 2 in bronchiolitis obliterans syndrome after lung transplantation. *Transplantation*. 2004;78(8):1222-4.
64. Oz MC, Ardehali A. Collective review: perioperative uses of inhaled nitric oxide in adults. *Heart Surg Forum*. 2004;7(6):E584-9.
65. Belperio JA, Keane MP, Burdick MD, Gomperts B, Xue YY, Hong K, Mestas J, Ardehali A, Mehrad B, Saggarr R, Lynch JP, Ross DJ, Strieter RM. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. *J Clin Invest*. 2005;115(5):1150-62.
66. Mitropoulos FA, Odim J, Marelli D, Karandikar K, Gjertson D, Ardehali A, Kobashigawa J, Laks H. Outcome of hearts with cold ischemic time greater than 300 minutes. A case-matched study. *Eur J Cardiothorac Surg*. 2005; 28(1):143-8.
67. Shargall Y, Guenther G, Ahya VN, Ardehali A, Singhal A, Keshavjee S. Report of the ISHLT working group on primary lung graft dysfunction part VI: Treatment. *J Heart Lung Transplant*. 2005;24(10):1489-500.
68. Belperio JA, Keane MP, Burdick MD, Gomperts BN, Xue YY, Hong K, Mestas J, Zisman D, Ardehali A, Saggarr R, Lynch JP, Ross DJ, Strieter RM. CXCR2/CXCR2 ligand biology during lung transplant ischemia-reperfusion injury. *J Immunol*. 2005;175(10):6931-9.
69. Kobashigawa JA, Laks H, Wu G, Patel J, Moriguchi J, Hamilton M, Fonarow G, Fishbein M, Ardehali A. The University of California at Los Angeles heart transplantation experience. *Clin Transpl*. 2005;173-85.

70. Schnickel GT, Ross DJ, Beygui R, Shefizadeh A, Laks H, Lynch J, Ardehali A. Modified reperfusion in clinical lung transplantation: the results of 100 consecutive cases. *J Thorac Cardiovasc Surg.* 2006;131(1):218-23.
71. Orens JB, Shearon TH, Freudenburger RS, Conte JV, Bhorade SM, Ardehali A. Thoracic organ transplantation in the United States, 1995-2004. *Am J Transplant.* 2006; 6(5):1188-97.
72. Schnickel GT, Hsieh G, Kachikwu EL, Garcia C, Shefizadeh A, Fishbein MC, Ardehali A. Role of CXCR3 and CCR5 in allograft rejection. *Transplant Proc.* 2006;38(10):3221-4.
73. Schnickel GT, Hsieh G, Garcia C, Shefizadeh A, Fishbein MC, Ardehali A. Cytoprotective gene HO-1 and chronic rejection in heart transplantation. *Transplant Proc.* 2006;38(10):3259-61.
74. Keane MP, Gomperts BN, Weight S, Xue YY, Burdick MD, Nakamura H, Zisman DA, Ardehali A, Saggarr R, Lynch JP 3rd, Hogaboam C, Kunkel SL, Lukacs NW, Ross DJ, Grusby MJ, Strieter RM, Belperio JA. IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. *J Immunol.* 2007;78(1):511-9.
75. Zisman DA, Ross DJ, Belperio JA, Saggarr R, Lynch JP 3rd, Ardehali A, Karlamangla AS. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. *Respir Med.* 2007;101(10):2153-9.
76. Zisman DA, Karlamangla AS, Ross DJ, Keane MP, Belperio JA, Saggarr R, Lynch JP 3rd, Ardehali A, Goldin J. High-resolution chest computer tomography findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. *Chest.* 2007;132(3):773-9.
77. Hsieh GR, Schnickel GT, Garcia C, Shefizadeh A, Fishbein MC, Ardehali A. Inflammation/oxidation in chronic rejection: Apolipoprotein A-I mimetic peptide reduces chronic rejection of transplanted hearts. *Transplantation.* 2007;84(2):238-43.
78. Mahidhara R, Bastani S, Ross DJ, Saggarr R, Lynch J 3rd, Schnickel GT, Gjertson D, Beygui R, Ardehali A. Lung transplantation in older patients? *J Thorac Cardiovasc Surg.* 2008;135(2):412-20.
79. Zisman DA, Karlamangla AS, Kawut SM, Shlobin OA, Saggarr R, Ross DJ, Schwarz MI, Belperio JA, Ardehali A, Lynch JP 3rd, Nathan SD. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. *Chest.* 2008;133(3):640-5.

80. Schnickel GT, Bastani S, Hsieh GR, Shefizadeh A, Bhatia R, Fishbein MC, Belperio J, Ardehali A. Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. *J Immunol*. 2008;180(7):4714-21.
81. Gregson AL, Hoji A, Saggar R, Ross DJ, Kubak BM, Jamieson BD, Weigt SS, Lynch JP 3rd, Ardehali A, Belperio JA, Yang OO. Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection. *Transplantation*. 2008;85(7):1056-1059.
82. Yu R, Yekta B, Vakili L, Gharavi N, Navab M, Marelli D, Ardehali A. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. *Curr Atheroscler Rep*. 2008;10(2):171-6.
83. Weigt SS, Elashoff RM, Keane MP, Strieter RM, Gomperts BN, Xue YY, Ardehali A, Gregson AL, Kubak B, Fishbein MC, Saggar R, Ross DJ, Lynch JP 3rd, Zisman DA, Belperio JA. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. *Am J Transplant*. 2008;8(7):1512-22.
84. Marelli D, Kobashigawa J, Hamilton MA, Moriguchi JD, Kermani R, Ardehali A, Patel J, Noguchi E, Beygui R, Laks H, Plunkett M, Shemin R, Esmailian F. Long-term outcomes of heart transplantation in older recipients. *J Heart Lung Transplant*. 2008; 27(8):830-4.
85. Saggar R, Ross DJ, Saggar R, Zisman DA, Gregson A, Lynch JP 3rd, Keane MP, Weigt SS, Ardehali A, Kubak B, Lai C, Elashoff D, Fishbein MC, Wallace WD, Belperio JA. Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft. *Am J Transplant*. 2008; 8(9):1921-30.
86. Belperio JA, Ardehali A. Chemokines and transplant vasculopathy. *Circ Res*. 2008;103(5):454-66.
87. Marelli D, Esmailian F, Wong SY, Kobashigawa JA, Kwon MH, Beygui RE, Laks H, Plunkett MD, Ardehali A, Shemin RJ. Tricuspid valve regurgitation after heart transplantation. *J Thorac Cardiovasc Surg*. 2009;137(6):1557-9.
88. Wu GW, Kobashigawa JA, Fishbein MC, Patel JK, Kittleson MM, Reed EF, Kiyosaki KK, Ardehali A. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. *J Heart Lung Transplant*. 2009;28(5):417-22.
89. Weigt SS, Elashoff RM, Huang C, Ardehali A, Gregson AL, Kubak B, Fishbein MC, Saggar R, Keane MP, Saggar R, Lynch JP 3rd, Zisman DA, Ross DJ, Belperio JA. *Aspergillus* colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. *Am J Transplant*. 2009;9(8):1903-11.

90. Kwon MH, Moriguchi JD, Ardehali A, Jocson R, Marelli D, Laks H, Shemin RJ, Esmailian F. Use of ventricular assist device as a bridge to cardiac transplantation: impact of age and other determinants on outcomes. *Tex Heart Inst J.* 2009;36(3):214-9.
91. Aboulhosn JA, Oudiz RJ, Dave AS, Ardehali A, Ross DJ. Successful tricuspid valve replacement in a patient with severe pulmonary arterial hypertension and preserved right ventricular systolic function. *Case Report Med.* 2009;108295.
92. Saggar R, Shapiro SS, Ross DJ, Fishbein MC, Zisman DA, Lynch JP 3rd, Weigt SS, Ardehali A, Belperio JA, Saggar R. Treprostinil to reverse pulmonary hypertension associated with idiopathic pulmonary fibrosis as a bridge to single-lung transplantation. *J Heart Lung Transplant.* 2009; 28(9):964-7.
93. Bastani S, Sherman W, Schnickel GT, Hsieh GR, Bhatia R, Fishbein MC, Ardehali A. Chemokine receptor blockade with a synthetic nonpeptide compound attenuates cardiac allograft vasculopathy. *Transplantation.* 2009; 88(8):995-1001.
94. Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, Lucke JC, Baltz JH, Novitzky D; Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group. On-pump versus off-pump coronary-artery bypass surgery. *N Engl J Med.* 2009;361(19):1827-37.
95. Khan TA, Schnickel G, Ross D, Bastani S, Laks H, Esmailian F, Marelli D, Beygui R, Shemin R, Watson L, Vartapetian I, Ardehali A. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. *J Thorac Cardiovasc Surg.* 2009; 138(6):1417-24.
96. Kobashigawa JA, Kiyosaki KK, Patel JK, Kittleson MM, Kubak BM, Davis SN, Kawano MA, Ardehali A. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. *J Heart Lung Transplant.* 2010;29(5):504-8.
97. Saggar R, Khanna D, Furst DE, Belperio JA, Park GS, Weigt SS, Kubak B, Ardehali A, Derhovanessian A, Clements PJ, Shapiro S, Hunter C, Gregson A, Fishbein MC, Lynch JP 3rd, Ross DJ, Saggar R. Systemic sclerosis and bilateral lung transplantation: a single center experience. *Eur Respir J.* 2010;36(4):893-900.
98. Lee C, Suh RD, Krishnam MA, Lai CK, Fishbein MC, Wallace WD, Chen A, Saggar R, Saggar R, Belperio JA, Ardehali A, Ross DJ. Recurrent Pulmonary Capillary Hemangiomatosis After Bilateral Lung Transplantation. *J Thorac Imaging.* 2010;25(3):W89-92.

99. Huang HC, Weigt SS, Derhovanessian A, Palchevskiy V, Ardehali A, Saggar R, Saggar R, Kubak B, Gregson A, Ross DJ, Lynch JP 3rd, Elashoff R, Belperio JA. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. *J Heart Lung Transplant*. 2011;30(7):790-8.
100. Zhang Q, Cecka JM, Gjertson DW, Ge P, Rose ML, Patel JK, Ardehali A, Kobashigawa JA, Fishbein MC, Reed EF, HLA and MICA: Targets of Antibody-Mediated Rejection in Heart Transplantation. *Transplantation*. 2011;91(10):1153-1158.
101. Kittleson MM, Shemin R, Patel JK, Ardehali A, Kawano M, Davis S, Moriguchi JD, Kobashigawa JA. Donor-recipient sex mismatch portends poor 10-year outcomes in a single-center experience. *J Heart Lung Transplant*. 2011;30(9):1018-22.
102. Moriguchi J, Davis S, Jocson R, Esmailian F, Ardehali A, Laks H, Kwon M, Kittleson M, Kobashigawa J, Patel J, Marelli D, Plunkett M, Beygui R, Shemin R. Successful use of a pneumatic biventricular assist device as a bridge to transplantation in cardiogenic shock. *J Heart Lung Transplant*. 2011;30(10):1143-7.
103. Sherman W, Rabkin DG, Ross D, Saggar R, Lynch JP 3rd, Belperio J, Saggar R, Hamilton M, Ardehali A. Lung transplantation and coronary artery disease. *Ann Thorac Surg*. 2011;92(1):303-8.
104. Deng MC, Ardehali A, Shemin R, Hickey An, MacLellan WR, Fonarow G. Relative roles of heart transplantation and long-term mechanical circulatory support in contemporary management of advanced heart failure – a critical appraisal 10 years after REMATCH. *Eur J Cardiothorac Surg*. 2011;40(4):781-2.
105. Weigt SS, Derhovanessian A, Liao E, Hu S, Gregson AL, Kubak BM, Saggar R, Saggar R, Plachevskiy V, Fishbein MC, Lynch JP 3rd, Ardehali A, Ross DJ, Wang HJ, Elashoff RM, Belperio JA. CXCR3 Chemokine Ligands During Respiratory Viral Infections Predict Lung Allograft Dysfunction. *Am J Transplant*. 2012;12(2):477-84.
106. Ross DJ, Strieter RM, Fishbein MC, Ardehali A, Belperio JA. Type I Immune Response Cytokine-Chemokine Cascade is Associated with Pulmonary Arterial Hypertension. *J Heart Lung Transplant*. 2012;31(8):865-73.
107. Shino MY, Weigt SS, Saggar R, Elashoff D, Derhovanessian A, Gregson AL, Saggar R, Reed EF, Kubak BM, Lynch JP 3rd, Belperio JA, Ardehali A, Ross DJ. Usefulness of immune monitoring in lung transplantation using adenosine triphosphate production in activated lymphocytes. *J Heart Lung Transplant*. 2012;31(9):996-1002.

108. Chang EI, Festekjian JH, Miller TA, Ardehali A, Rudkin GH. Chest Wall Reconstruction for Sternal Dehiscence After Open Heart Surgery. *Ann Plast Surg.* 2013;71(1):84-7.
109. Kwon MH, Wong SY, Ardehali A, Laks H, Zhang ZK, Deng MC, Shemin RJ. Primary graft dysfunction does not lead to increased cardiac allograft vasculopathy in surviving patients. *J Thorac Cardiovasc Surg.* 2013;145(3):869-73.
110. Gregson AL, Wang X, Weigt SS, Palchevskiy V, Lynch JP 3rd, Ross DJ, Kubak BM, Saggarr R, Fishbein MC, Ardehali A, Li G, Elashoff R, Belperio JA, Interaction Between Pseudomonas and CXCL Chemokines Increases Risk of BOS and Death in Lung Transplantation. *Am J Respir Crit Care Med.* 2013;187(5):518-26.
111. Weigt SS, Copeland CA, Derhovanessian A, Shino MY, Davis WA, Snyder LD, Gregson AL, Saggarr R, Lynch JP 3rd, Ross DJ, Ardehali A, Elashoff RM, Palmer SM, Belperio JA. Colonization with small conidia aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study. *Am J Transplant.* 2013;13(4):919-27.
112. Shino MY, Weigt SS, Li N, Palchevskiy V, Derhovanessian A, Saggarr R, Sayah DM, Gregson AL, Fishbein MC, Ardehali A, Ross DJ, Lynch JP 3rd, Elashoff RM, Belperio JA. CXCR3 Ligands Are Associated with the Continuum of Diffuse Alveolar Damage to Chronic Lung Allograft Dysfunction. *Am J Respir Crit Care Med.* 2013;188(9):1117-25.
113. Yadlapati A, Lynch JP 3rd, Saggarr R, Ross D, Belperio JA, Weigt S, Ardehali A, Grogan T, Yang EH, Aboulhosn J. Preoperative cardiac variables of diastolic dysfunction and clinical outcomes in lung transplant recipients. *J Transplant.* 2013;2013:391620.
114. Bui KT, Mehta S, Khuu TH, Ross D, Carlson M, Leibowitz MR, Schaenman JM, Saggarr R, Lynch JP 3rd, Ardehali A, Kubak BM. Extended Spectrum β -Lactamase-Producing Enterobacteriaceae Infection in Heart and Lung Transplant Recipients and in Mechanical Circulatory Support Recipients. *Transplantation.* 2014;97(5):590-4.
115. Ebrahimi R, Bakaeen FG, Uberoi A, Ardehali A, Baltz JH, Hattler B, Almassi GH, Wagner TH, Collins JF, Grover FL, Shroyer AL. Effect of Clopidogrel Use Post Coronary Artery Bypass Surgery on Graft Patency. *Ann Thorac Surg.* 2014; 97(1):15-21.

116. Larson ES, Khalil HA, Lin AY, Russell M, Ardehali A, Ross D, Yoo J. Diverticulitis occurs early after lung transplantation. *J Surg Res.* 2014;190(2):667-71.
117. Kwon MH, Wong S, Kittleson M, Ardehali A, Laks H, Shemin RJ, Kobashigawa J. Selecting oversized donor cardiac allografts for patients with pulmonary hypertension may be unnecessary. *Transplant Proc.* 2014;46(5):1497-501.
118. Gabel E, Gudzenko V, Cruz D, Ardehali A, Fink MP. Successful use of extracorporeal membrane oxygenation in an adult patient with toxic shock-induced heart failure. *J Intensive Care Med.* 2015;30(2):115-8.
119. Messer S, Ardehali A, Tsui S. Normothermic donor heart perfusion: current clinical experience and the future. *Transpl Int.* 2015;28(6):634-42.
120. Sayah DM, Mallavia B, Liu F, Ortiz-Muñoz G, Caudrillier A, DerHovanessian A, Ross DJ, Lynch Iii JP, Sagggar R, Ardehali A, Ware LB, Christie JD, Belperio JA, Looney MR; Lung Transplant Outcomes Group Investigators. Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation. *Am J Respir Crit Care Med.* 2015;191(4):455-63.
121. Gregson AL, Wang X, Injean P, Weigt SS, Shino M, Sayah D, DerHovanessian A, Lynch JP 3rd, Ross DJ, Sagggar R, Ardehali A, Li G, Elashoff R, Belperio JA. Staphylococcus via an Interaction With the ELR+ CXC Chemokine ENA-78 Is Associated With BOS. *Am J Transplant.* 2015;15(3):792-9.
122. Kwon MH, Zhang JQ, Schaenman JM, Cadeiras M, Gjertson DW, Krystal CA, Laks H, Ardehali A, Deng MC, Shemin RJ, Reed EF. Characterization of ventricular assist device-mediated sensitization in the bridge-to-heart-transplantation patient. *J Thorac Cardiovasc Surg.* 2015;149(4):1161-6
123. Ardehali A, Esmailian F, Deng M, Soltesz E, Hsich E, Naka Y, Mancini D, Camacho M, Zucker M, Leprince P, Padera R, Kobashigawa J. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. *Lancet.* 2015;385(9987):2577-84.
124. Gregson AL, Hoji A, Injean P, Poynter ST, Briones C, Palchevskiy V, Sam Weigt S, Shino MY, Derhovanessian A, Sayah D, Sagggar R, Ross D, Ardehali A, Lynch JP 3rd, Belperio JA. Altered Exosomal RNA Profiles in Bronchoalveolar Lavage from Lung Transplants with Acute Rejection. *Am J Respir Crit Care Med.* 2015;192(12):1490-503.
125. Ross DJ, Hough G, Hama S, Aboulhosn J, Belperio JA, Sagggar R, Van Lenten BJ, Ardehali A, Eghbali M, Reddy S, Fogelman AM, Navab M. Proinflammatory

- high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension. *Pulm Circ.* 2015;5(4):640-8.
126. DerHovanessian A, Weigt SS, Palchevskiy V, Shino MY, Sayah DM, Gregson AL, Noble PW, Palmer SM, Fishbein MC, Kubak BM, Ardehali A, Ross DJ, Sagggar R, Lynch JP 3rd, Elashoff RM, Belperio JA. The Role of TGF- β in the Association Between Primary Graft Dysfunction and Bronchiolitis Obliterans Syndrome. *Am J Transplant.* 2016;16(2):640-9.
 127. Biniwale R, Ross D, Iyengar A, Kwon OJ, Hunter C, Aboulhosn J, Gjertson D, Ardehali A. Lung transplantation and concomitant cardiac surgery: Is it justified? *J Thorac Cardiovasc Surg.* 2016;151(2):560-7.
 128. Miele CH, Schwab K, Sagggar R, Duffy E, Elashoff D, Tseng CH, Weigt S, Charan D, Abtin F, Johannes J, Derhovanessian A, Conklin J, Ghassemi K, Khanna D, Siddiqui O, Ardehali A, Hunter C, Kwon M, Biniwale R, Lo M, Volkmann E, Torres Barba D, Belperio JA, Sayah D, Mahrer T, Furst DE, Kafaja S, Clements P, Shino M, Gregson A, Kubak B, Lynch JP 3rd, Ross D, Sagggar R. Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. *Ann Am Thorac Soc.* 2016;13(6):793-802.
 129. Tran BG, De La Cruz K, Grant Meltzer J, Benharash P, Dave R, Ardehali A, Shemin R, Depasquale E, Nsair A. Temporary Venoarterial Extracorporeal Membrane Oxygenation: Ten Year Experience at a Cardiac Transplant Center. *J Intensive Care Med.* 2016 Jun 14.: Epub ahead of print.
 130. Allyn PR, Duffy EL, Humphries RM, Injean P, Weigt SS, Sagggar R, Shino MY, Lynch JP 3rd, Ardehali A, Kubak B, Tseng CH, Belperio JA, Ross DJ, Gregson AL. Graft Loss and Clad Onset is Hastened by Viral Pneumonia After Lung Transplantation. *Transplantation.* 2016;100(11):2424-2431.
 131. Kolaitis NA, Duffy E, Zhang A, Lo M, Barba DT, Chen M, Soriano T, Hu J, Nabili V, Sagggar R, Sayah DM, DerHovanessian A, Shino MY, Lynch JP 3rd, Kubak BM, Ardehali A, Ross DJ, Belperio JA, Elashoff D, Sagggar R, Weigt SS. Voriconazole Increases the Risk for Cutaneous Squamous Cell Carcinoma after Lung Transplantation. *Transpl Int.* 2017;30(1):41-48
 132. Shino MY, Weigt SS, Li N, Derhovanessian A, Sayah DM, Huynh RH, Sagggar R, Gregson SL, Ardehali A, Ross DJ, Lynch JP 3rd, Elashoff RM, Belperio JA. Impact of allograft injury time-of-onset on the development of chronic lung allograft dysfunction after lung transplantation. *Am J Transplant.* 2017;17(5):1294-1303

133. Weigt SS, Wang X, Palchevskiy V, Patel N, Derhovanessian A, Shino MY, Sayah DM, Gregson AL, Lynch JP 3rd, Sagggar R, Ross DJ, Ardehali A, Elashoff D, Belperio JA. Gene Expression Profiling of Bronchoalveolar Lavage Cells Preceding a Clinical Diagnosis of Chronic Lung Allograft Dysfunction. *PLoS One*. 2017;12(1):e0169894.
134. Iyengar A, Kwon OJ, Tamrat M, Salimbangon A, Satou N, Benharash P, Ardehali A, Shemin RJ, Kwon MH. The In-Hospital Cost of Ventricular Assist Device Therapy: Implications for Patient Selection. *ASAIO J*. 2017;63(6):725-730
135. Shino MY, Weigt SS, Li N, Palchevskiy V, Derhovanessian A, Sagggar R, Sayah DM, Huynh RH, Gregson AL, Fishbein MC, Ardehali A, Ross DJ, Lynch JP 3rd, Elashoff RM, Belperio JA. The prognostic importance of CXCR3 chemokine during organizing pneumonia on the risk of chronic lung allograft dysfunction after lung transplantation. *PLoS One*. 2017;12(7):e0180281.
136. Shroyer AL, Hattler B, Wagner TH, Collins JF, Baltz JH, Quin JA, Almassi GH, Kozora E, Bakeen F, Cleveland JC, Bishawi M, Grover FL, Veterans Affairs ROOBY-FS Group. Five-Year Outcome after On-Pump and Off-Pump Coronary Artery Bypass. *New Eng J Med*. 2017;377(7):623-32.
137. Weigt SS, Wang X, Palchevskiy V, Patel N, Derhovanessian A, Shino MY, Sayah DM, Gregson AL, Lynch JP 3rd, Sagggar R, Ross DJ, Ardehali A, Elashof D, Belperio JA. Gene Expression Profiling of Bronchoalveolar Lavage Cells Preceding a Clinical Diagnosis of Chronic Lung Allograft Dysfunction. *Ann Am Thorac Soc*. 2017;Supplement 3:S252.
138. Weigt SS, Wang X, Palchevskiy V, Patel N, Derhovanessian A, Shino MY, Sayah DM, Lynch JP 3rd, Sagggar R, Ross DJ, Kubak BM, Ardehali A, Palmer S, Husain S, Belperio JA. Gene Expression Profiling of Bronchoalveolar Lavage Cells during *Aspergillus* Colonization of the Lung Allograft. *Transplantation*. 2017 Dec 18: Epub ahead of print.
139. Bakir M, Jackson NJ, Han SX, Bui A, Chang E, Liem DA, Ardehali A, Ardehali R, Baas AS, Press MC, Cruz D, Deng MC, DePasquale EC, Fonarow GC, Khuu T, Kwon MH, Kubak BM, Nsair A, Phung JL, Reed EF, Schaenman JM, Shemin RJ, Zhang QJ, Tseng CH, Cadeiras M. Clinical phenomapping and outcomes after heart transplantation. *J Heart Lung Transplant*. 2018 Mar 22. pii: S1053-2498(18)31391-3
140. Warnecke G, Van Raemdonck D, Smith MA, Massard G, Kukreja J, Rea F, Loor G, De Robertis F, Nagendran J, Dhital KK, Moradiellos Díez FJ, Knosalla C, Bermudez CA, Tsui S, McCurry K, Wang IW, Deuse T, Lesèche G, Thomas P, Tudorache I, Kühn C, Avsar M, Wiegmann B, Sommer W, Neyrinck A, Schiavon

- M, Calabrese F, Santelmo N, Olland A, Falcoz PE, Simon AR, Varela A, Madsen JC, Hertz M, Haverich A, Ardehali A. Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study. *Lancet Respir Med.* 2018 May;6(5):357-367.
141. Tran BG, De La Cruz K, Grant S, Meltzer J, Benharash P, Dave R, Ardehali A, Shemin R, Depasquale E, Nsair A. Temporary Venoarterial Extracorporeal Membrane Oxygenation: Ten-Year Experience at a Cardiac Transplant Center. *J Intensive Care Med.* 2018 May;33(5):288-295
 142. Iyengar A, Kwon OJ, Sanaiha Y, Eisenring C, Biniwale R, Ross D, Ardehali A. Lung transplantation in the lung allocation score era: Medium-term analysis from a single center. *Clin Transplant.* 2018 May 27:e13298.
 143. Weigt SS, Wang X, Palchevskiy V, Patel N, Derhovanessian A, Shino MY, Sayah DM, Lynch JP 3rd, Saggarr R, Ross DJ, Kubak BM, Ardehali A, Palmer S, Husain S, Belperio JA. Gene Expression Profiling of Bronchoalveolar Lavage Cells During *Aspergillus* Colonization of the Lung Allograft. *Transplantation.* 2018 Jun;102(6):986-993.
 144. DePasquale EC, Ardehali A. Primary graft dysfunction in heart transplantation. *Curr Opin Organ Transplant.* 2018 Jun;23(3):286-294.
 145. Ardehali A. Evolving challenges in thoracic transplantation. *Curr Opin Organ Transplant.* 2018 Jun;23(3):279-280.

BOOK CHAPTERS

1. Ardehali A, Cheitlin MD. Acute aortic and mitral valvular regurgitation, in Parmley WW and Chatterjee K (eds): *Cardiology*. New York, Lippincott, 1991
2. Ardehali A, Laks H, Fyfe AI. Gene transfer and intrathoracic transplantation, in Cooper DKC (ed): *Transplantation and Replacement of Thoracic Organs*, Second Edition, 1996
3. Marelli D, Laks H, Bresson J, Houston E, Tsai FC, Hamilton M, Moriguchi J, Fonarow GC, Ardehali A, Camara R, Burch C, Alejos JC, George B, Kawata N, Kobashigawa J. Sixteen-Year experience with 1000 heart transplants at UCLA. *Clinical Transplant 2000*, Cecka and Terasaki, Eds. UCLA Immunogenetics Center, Los Angeles. 1-14
4. Whiting D, Ardehali, A. Animal Models for Xenotransplantation. *Handbook of Laboratory Animal Science*, Second Edition: *Animal Models*, Volume II, 2003

5. Kobashigawa JA, Laks H, Wu G, Patel J, Moriguchi J, Hamilton M, Fonarow G, Fishbein M, Ardehali A. The University of California at Los Angeles heart transplantation experience. *Clinical Transplant* 2005;173-85.
6. Kobashigawa JA, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Davis SN, Moriguchi JD, Reed EF, Ardehali AA. The long-term outcome of treated sensitized patients who undergo heart transplantation. *Clin Transplant*. 2011 Jan-Feb;25(1):E61-7.
7. Parsons P, Wiener-Kronish, J, Ardehali A. *Critical Care Secrets, Fifth Edition*, 2012.
8. Wickii Vigneswaran, Edward Garrity and John Odell, *Lung Transplantation: Principles and Practice*, 2016; Chapter 25: Lung Transplantation for Connective Tissue Disorders

BOOK ASSOCIATE EDITOR

1. Khonsari S, Sintek CF, Ardehali A. *Cardiac surgery: Safeguards and pitfalls in operative technique*, Fourth Edition, 2008.

BOOK EDITOR

1. Khonsari's *Cardiac surgery: Safeguards and pitfalls in operative technique*, Fifth Edition, 2016.

ABSTRACTS

1. Ardehali A, Cheitlin MD, Segal J. Disappearance of coronary flow reserve and changes in coronary flow velocity pattern in acute aortic regurgitation using an intracoronary doppler guidewire. *American Heart Association*, Atlanta, GA, 11/90
2. Ardehali A, Billingsley A, Laks H, Drinkwater DC, Drake TA. Experimental Cardiac allograft vasculopathy in mice. *ISHLT Annual Meeting*. Boca Raton, FL, 4/93
3. Ardehali A, Laks H, Drinkwater DC, Kato NS, Permut LC, Grant PW, Aharon AS, Drake TA. The impact of cold storage of cardiac allografts on expression of MHC antigens and vascular adhesion molecules. *ISHLT Annual Meeting*. Boca Raton, FL, 4/93
4. Laks H, Drinkwater DC, Ardehali A, Grant PW, Galindo A, George B. Heart Transplantation in Children. *ISHLT Annual Meeting* Geneva, Switzerland, 5/93

5. Laks H, Aharon A, Drinkwater DC, Gates RN, Kobashigawa JA, Stevenson LW, Ardehali A, Rudis E. Ischemic cardiomyopathy: Results of heart transplantation and coronary revascularization. ISHLT Annual Meeting. Geneva, Switzerland, 5/93
6. Fyfe AI, Ardehali A, Qiao JH, Drinkwater DC, Laks H, Stevenson LW, Lysis AJ. Expression of a peri-operatively transferred reporter gene in a functioning mouse cardiac isograft. Canadian Cardiovascular Society, Vancouver, B.C. 10/93
7. Laks H, Grant P, Ardehali A, Permut LC, Jones J, Aharon A, Galindo A. Fontan with unidirectional cavopulmonary connection: A novel approach. American Heart Association, Atlanta, GA, 11/93
8. Ardehali A, Fyfe AI, Laks H, Drinkwater DC, Qiao JH, Lysis AJ. Transfection of transplanted mouse hearts by intracoronary infusion of a reporter plasmid. American Heart Association, Atlanta, GA, 11/93
9. Aharon A, Laks H, Drinkwater DC, Esmailian F, Ziv E, Permut L, Ardehali A. Cerebral retroperfusion as an adjunct to prolongs hypothermic circulatory arrest. American College of Surgeons, Southern California Chapter, Newport Beach, CA, 1/94
10. Ardehali A, Drinkwater DC, Grant PW, George B, Galindo A, Laks H. Pediatric Heart Transplantation at UCLA. American College of Surgeons, Southern California Chapter, Newport Beach, CA, 1/93
11. Ardehali A, Zuckerbraun L. Autonomous Toxic Thyroid Nodule. American College of Surgeons, Southern California Chapter, Newport Beach, CA, 1/94
12. Fyfe AI, Ardehali A, Laks H, Lysis AJ. Intracoronary liposome mediated gene transfer of human HLA-B7 into mouse isografts at the time of transplantation produces acute cellular rejection. Keystone Symposium, 1/94
13. Ardehali A, Laks H, Drinkwater D, Grant P, George B, Galindo A. Heart transplantation for congenital heart diseases. American College of Cardiology, Atlanta, GA, 3/94
14. Aharon A, Laks H, Drinkwater DC, Chugh R, Gates RN, Grant PW, Permut LC, Ardehali A. Early and late results of mitral valve repair in children. American Association of Thoracic Surgery, New York, NY, 4/94
15. Ardehali A, Laks H, Gates RN, Drinkwater DC, Sorensen TJ, Chang P. The capillary distribution of retrograde cardioplegia in explanted human hearts. American association of Thoracic Surgery, New York, NY, 4/94

16. Ardehali A, Laks H, Fyfe AI, Drinkwater DC, Qiao JH, Lusic AJ. Can donor hearts be genetically altered prior to transplantation? American Association of Thoracic Surgery, New York, NY, 4/94
17. Rudis E, Gates RN, Laks H, Drinkwater DC, Ardehali A, Aharon A, Chang P. Coronary sinus ostial occlusion during retrograde cardioplegia delivery significantly improves cardioplegic distribution and efficacy. Western Thoracic Surgical Association, 6/94
18. Ardehali A, Laks H, Drinkwater DC, Kobashigawa J, Moriguchi J, Drake TA. Vascular cell Adhesion Molecule-1 up-regulation precedes and predicts cellular rejection of human cardiac allografts. American College of Surgeons, Chicago, IL, 10/94
19. Ardehali A, Laks H, Drinkwater DC, Gates RN, Sorensen T, Chang P. Does the thebesian venous effluent of retrograde cardioplegia in the human heart have nutritive properties? The Society of Thoracic Surgeons, 31st Annual Meeting, Palm Springs, CA, 2/95
20. Ardehali A, Laks H, Drinkwater DC, Rudis E, Hiramoto J, Bree M, Chang P. Selective inhibition of neutrophil adhesion during reperfusion improves functional recovery of transplanted hearts ISHLT Annual Meeting. 4/95
21. Ardehali A, Kessler D, Foroushani F, Laks H. Coronary bypass surgery without cardiopulmonary bypass. American College of Surgeons, Southern California Chapter, Santa Barbara, CA, 1/99
22. Ardehali A, Laks H, Kessler D, Foroushani F, Esmailian F. Complete myocardial revascularization on a beating heart. Evolving Techniques and Technologies in Minimally Invasive Cardiac Surgery. San Antonio, TX 1/99
23. Ardehali A, Chait H, Levine M, Shpiner R, Laks H, Watson L, Shvartz O, Sangwan S, Waters PF. A prospective trial of Nitric Oxide in clinical lung transplantation. The Society of Thoracic Surgeons, San Antonio, TX 1/99
24. Yun JJ, Fischbein MP, Fishbein MC, Laks H, Espejo M, Ardehali A. Reperfusion Induces MCP-1/JE, MIP-2 gene up-regulation and cellular recruitment in transplanted hearts. Society of University Surgeons 60th Meeting, 2/99
25. Fischbein MP, Yun JJ, Laks H, Fishbein MC, Espejo M, Ebrahimi K, Bonavida B, Ardehali A. Temporal pattern of T lymphocyte and macrophage infiltration in a nonimmunosuppressed model of CAV. ISHLT Annual Meeting. San Francisco, CA, 4/99

26. Yun JJ, Fischbein MP, Laks H, Fishbein MC, Espejo M, Ebrahimi K, Ardehali A. Lymphotactin mediates t cell recruitment in Cardiac Allograft Vasculopathy. FASEB, Washington, DC, 4/99
27. Fischbein MP, Yun JJ, Laks H, Fishbein MC, Ardehali A, Bonavida B. CD8+ T cells participate in Cardiac Allograft Vasculopathy. FASEB, Washington, DC, 4/99
28. Yun JJ, Fischbein MP, Laks H, Fishbein MC, Espejo M, Ebrahimi K, Ardehali A. Chemokine expression and cellular infiltrate in Cardiac Allograft Vasculopathy. American Society of Transplantation, Chicago, IL, 5/99
29. Yun JJ, Fischbein MP, Laks H, Fishbein MC, Espejo M, Ebrahimi K, Ardehali A. Chemokines MIP-2 and MCP-1/JE mediate leukocyte recruitment after reperfusion. American Society of Transplantation, Chicago, IL, 5/99
30. Yun JJ, Fischbein MP, Laks H, Fishbein MC, Shiroishi M, Ardehali A. Ischemia time prolongation does not promote chemokine gene expression or leukocyte recruitment after heart transplantation. American Society of Transplantation, Chicago, IL, 5/99
31. Fischbein MP, Yun JJ, Laks H, Fishbein MC, Ebrahimi K, Bonavida B, Ardehali A. CD4+ T lymphocytes are necessary for development of Cardiac Allograft Vasculopathy. American Society of Transplantation, Chicago, IL, 5/99
32. Esmailian F, Laks H, Kessler D, Foroushani F, Ardehali A. Off-pump, complete myocardial revascularization via median sternotomy: Early results. Western Thoracic Surgical Association, Lake Tahoe, CA, 6/99
33. Yun JJ, Fischbein MP, Laks H, Fishbein MC, Espejo M, Ebrahimi K, Ardehali A. Cardiac Allograft Vasculopathy is a Th-1 Cytokine Dependent process. American College of Surgeons, 10/99
34. Fischbein MP, Yun JJ, Laks H, Fishbein MC, Espejo M, Bonavida B, Ardehali A. Chronic rejection in heart transplantation requires CD40L-CD40 engagement. American College of Surgeons, 10/99
35. Hughes K, Waters P, Chait H, Levine M, Shpiner R, Laks H, Ardehali A. Nitric Oxide and lung transplantation. American College of Surgeons, Southern California Chapter, Laguna Beach, CA, 1/00
36. Fischbein MP, Yun JJ, Laks H, Bonavida B, Ardehali A. Immune mechanisms in chronic rejection of transplanted hearts. American College of Surgeons, Southern California Chapter, Laguna Beach, CA, 1/00

37. Ardehali A, Chait H, Sadeghi AM, Esmailian F, Marelli D, Moriguchi J, Hamilton M, Kobashigawa J, Laks H. A prospective trial of nitric oxide in heart transplant recipients with pulmonary hypertension. The Society of Thoracic Surgeons, Fort Lauderdale, FL, 1/00
38. Fischbein MP, Yun JJ, Laks H, Irie Y, Fishbein MC, Espejo M, Bonavida B, Ardehali A. Signalling through CD40 can replace the requirement of CD4+ lymphocytes in Cardiac Allograft Vasculopathy. ISHLT Annual Meeting. Osaka, Japan, 4/00
39. Fischbein MP, Yun JJ, Laks H, Irie Y, Fishbein MC, Espejo M, Bonavida B, Ardehali A. CD8 + lymphocytes accentuate Cardiac Allograft Vasculopathy via crosspriming. ISHLT Annual Meeting. Osaka, Japan, 4/00
40. Fischbein MP, Yun JJ, Laks H, Irie Y, Fishbein MC, Espejo M, Bonavida B, Ardehali A. CD4+ helper function is delivered via the secretion of IFN- γ . ISHLT Annual Meeting. Osaka, Japan, 4/00
41. Yun JJ, Fischbein MP, Laks H, Fishbein MC, Espejo M, Irie Y, Berliner J, Ardehali A. Intragraft CD4+ lymphocytes are required for RANTES production early in Cardiac Allograft Vasculopathy. ISHLT Annual Meeting. Osaka, Japan, 4/00
42. Marelli D, Laks H, Fazio D, Sadeghi A, Ardehali A, Moriguchi J, Houston E, Talamo M, Esmailian F, Hage A, Hamilton M, Fonarow G, Kwata N, Kobashigawa J. The use of marginal donor hearts. ISHLT Annual Meeting. Osaka, Japan, 4/00
43. Laks H, Marelli D, Fazio D, Sadeghi A, Ardehali A, Hamilton M, Moriguchi J, Fonarow G, Hage A, Esmailian F, Kwata N, Kobashigawa J. Intermediate term results of the alternate recipient list for heart transplantation. ISHLT Annual Meeting. Osaka, Japan, 4/00
44. Marelli D, Laks H, Moriguchi J, Fazio D, Meehan D, Talamo M, Sadeghi A, Esmailian F, Ardehali A. Short term bridge to transplant using the BVS 5000 ventricular assist device. American Society of Transplantation, Chicago, IL, 5/00
45. Buljubasic N, Laks H, Esmailian F, Marelli D, Sadeghi A, Ardehali A, Moriguchi J, Kobashigawa. Comparison of QID and BID regimen for initiation of cyclosporine treatment following heart transplantation. American Society of Transplantation, Chicago, IL, 5/00
46. Marelli D, Laks H, Sadeghi A, Moriguchi J, Fazio D, Houston E, Talamo M, Esmailian F, Ardehali A, Hage A, Hamilton M, Fonarow G, Kwata N, Kobashigawa J. Single institution outcome analysis of 344 consecutive patients

- receiving donor hearts preserved using University of Wisconsin solution. American Society of Transplantation, Chicago, IL, 5/00
47. Fischbein MP, Yun JJ, Laks H, Irie Y, Fishbein MC, Espejo M, Bonavida B, Ardehali A. IL-10 transgene prevents cardiac allograft vasculopathy. American Society of Transplantation, Chicago, IL, 5/00
 48. Yun JJ, Fischbein MP, Laks H, Fishbein MC, Espejo M, Irie Y, Berliner J, Ardehali A. RANTES production parallels T cell recruitment and precedes CAV development in MHC I and II incompatible cardiac allografts. American Society of Transplantation, Chicago, IL, 5/00
 49. Yun JJ, Fischbein MP, Laks H, Fishbein MC, Irie Y, Espejo M, Berliner J, Rajavashisth TB, Ardehali A. CSF-1 deficiency accelerates cardiac allograft rejection. American Society of Transplantation, Chicago, IL, 5/00
 50. Marelli D, Fazio D, Laks H, Esmailian F, Ardehali A, Plunkett M, Sadeghi A. Mechanical cardiac assistance using the BVS 5000: Five-year experience. ASAIO, New York, NY, 6/00
 51. Hughes K, Laks H, Sadeghi A, Esmailian F, Marelli D, Moriguchi J, Hamilton M, Kobashigawa J, Ardehali A. Nitric Oxide and Heart Transplantation. American College of Surgeons, Southern California Chapter, Santa Barbara, CA, 1/01
 52. Yun J, Fischbein MP, Laks H, Fishbein MC, Espejo M, Berliner J, Ardehali A. Production of the Chemokine RANTES in Transplant Coronary Artery Disease. American College of Surgeons, Southern California Chapter, Santa Barbara, CA, 1/01
 53. Marelli D, Tsai F, Laks H, Houston E, Bresson J, Friend L, Gjertson D, Sykes A, Ardehali A, Esmailian F, Hamilton M, Fonarow G, Moriguchi J, Plunkett M, Hage A, Brown M, Mark M, Kobashigawa J. Use of hearts transplanted from donors with atraumatic intracranial bleeds. ISHLT Annual Meeting. Vancouver, Canada, 4/01
 54. Fischbein MP, Yun J, Laks H, Fishbein MC, Irie Y, Wortham C, Bonavida B, Ardehali A. CD8+ lymphocytes participate in the development of chronic rejection. ISHLT Annual Meeting. Vancouver, Canada, 4/01
 55. Yun J, Fischbein MP, Laks H, Fishbein M, Irie Y, Espejo M, Berliner JA, Ardehali A. Sustained RANTES production is necessary for CAV development. ISHLT Annual Meeting. Vancouver, Canada, 4/01
 56. Ross DJ, Chan RC, Kubak B, Ardehali A, Laks H, Nichols WS. Bronchiolitis obliterans with organizing pneumonia: possible association with human herpes

- virus-7 infection after lung transplantation. ISHLT Annual Meeting. Vancouver, Canada, 4/01
57. Yun J, Fischbein MP, Laks H, Fishbein MC, Irie Y, Strieter R, Berliner JA, Ardehali A. Sustained production of the chemokine MIG precedes intimal thickening in rejection. ISHLT Annual Meeting. Vancouver, Canada, 4/01
 58. Yun J, Fischbein MP, Laks H, Fishbein M, Wortham C, Irie Y, Ardehali A. Cross-priming in chronic rejection. American Society of Transplantation, Chicago, IL, 5/01
 59. Yun Y, Fischbein MP, Laks H, Fishbein M, Irie Y, Ardehali A. Development of cardiac allograft vasculopathy in H2M deficient mice. American Society of Transplantation, Chicago, IL, 5/01
 60. Yun J, Fischbein MP, Laks H, Fishbein M, Irie Y, Strieter R, Berliner J, Ardehali A. RANTES neutralization reduces mononuclear cell infiltration and intimal thickening in cardiac allograft vasculopathy. American Society of Transplantation, Chicago, IL, 5/01
 61. Yun J, Fischbein MP, Laks H, Fishbein M, Irie Y, Strieter R, Berliner J, Ardehali A. Production of Mig and CXCR3 in chronic rejection. American Society of Transplantation, Chicago, IL, 5/01
 62. Russell H, Laks H, Ross D, Levine M, Sphiner R, Ardehali A. Modified Reperfusion in human lung transplantation. American College of Surgeons, Southern California Chapter, Santa Barbara, CA, 1/02
 63. Odim J, Laks H, Kobashigawa J, Alikhani A, Ardehali A. Early outcome of primary graft failure following orthotopic heart transplantation. American Society of Transplant Surgeons Winter Symposium, Miami Beach, Florida, 1/02.
 64. Russell H, Laks H, Ross D, Levine M, Sphiner R, Ardehali A. Modified reperfusion decreases the incidence of reperfusion injury in human lung transplantation. American Society of Transplant Surgeons Winter Symposium, Miami Beach, Florida, 1/02
 65. Marelli D, Negahban A, Kermani R, Tsai F-C, Fischer W, Ardehali A, Laks H. Use of University of Wisconsin solution with leukocyte depleted reperfusion in 464 consecutive heart transplant recipients. American Society of Transplant Surgeons Winter Symposium, Miami Beach, Florida, 1/02
 66. Whiting D, Ross D, Laks H, Levine M, Shpiner R, Ardehali A. Is prophylactic administration of inhaled NO in human lung transplantation more effective in treatment of reperfusion injury than initiation of treatment upon diagnosis?

American Society of Transplant Surgeons Winter Symposium, Miami Beach, Florida, 1/02

67. Whiting D, Yun J, Fischbein MP, Berliner J, Fishbein MC, Laks H, Ardehali A. Chemokine expression in ischemia-reperfusion injury. American Society of Transplant Surgeons Winter Symposium, Miami Beach, Florida, 1/02
68. Ross DJ, Ardehali A, Laks H, Hariharan K, Strieter RS, Clements P. Increased prevalence of antiphospholipid antibodies in primary and secondary pulmonary and arterial hypertension. ISHLT Annual Meeting. Washington, DC, 4/02
69. Ross DJ, Cole AM, Park A, Yoshioka D, Strieter RS, Belperio J, Kubak B, Laks H, Ardehali A, Ganz T. Increased BAL Human B-Defensin-2 Bronchiolitis Obliterans Syndrome after lung transplantation. ISHLT Annual Meeting. Washington, DC, 4/02
70. Patel B, Marelli D, Patel J, Tsai F-C, Moriguchi J, Fonarow G, Hamilton M, Ardehali A, Esmailian F, Plunkett M, Hage A, Kobashigawa J, Laks H. Heart transplantation in patients with diabetes mellitus in the current era. ISHLT Annual Meeting. Washington, DC, 4/02
71. Laks H, Marelli D, Bresson S, Bresson J, Ardehali A, Esmailian F, Plunkett M, Moriguchi J, Kobashigawa J. Use of donor hearts with coronary artery disease. ISHLT Annual Meeting. Washington, DC, 4/02
72. Ross DJ, Clements P, Ardehali A, Laks H, Burdick MD, Hariharan K, Strieter RS. Pulmonary Arterial Hypertension (PAH) is associated with increased capillary blood proangiogenic C-X-C chemokines. ISHLT Annual Meeting. Washington, DC, 4/02
73. Ardehali A, Laks H, Russell H, Levine M, Shpiner R, Ross D. Modified Reperfusion Decreases the Incidence of Ischemia-Reperfusion Injury in Human Lung Transplantation. Western Thoracic Surgical Association, Big Sky, Montana, 6/02
74. Whiting D, Yun J, Fischbein M, Burdick M, Strieter R, Fishbein M, Laks H, Berliner J, Ardehali A. Chemokine IP-10 and Cardiac Allograft Vasculopathy. XIX International Congress of The Transplantation Society, Miami, FL, 8/02
75. Whiting D, Fischbein M, Yun J, Chun S, Bonavida B, Ardehali A. CD8 Lymphocytes Recognize Disparate MHC II Antigens Via Cross-Priming and the Direct Pathway. XIX International Congress of The Transplantation Society, Miami, FL, 8/02

76. Whiting D, Chun S, Laks H, Yun J, Gan X-H, Yao W, Bonavida B, Ardehali A. MIG/CXCL9 Neutralization Attenuates Chronic Rejection of Transplanted Hearts. ISHLT Annual Meeting. Vienna, Austria, 4/03
77. Belperio JA, Keane MP, Burdick MD, Addison CL, Lynch JP III, Londhe V, Xue YY, Ardehali A, Ross DJ, Strieter RM. Critical Role for IL-10 Cytokine Biology in the Pathogenesis of Acute Lung Allograft Rejection. American Thoracic Society, Anchorage, AK, 5/03
78. Whiting D, Banerji A, Laks H, Chun S, Yao W, Gan X-H, Bonavida B, Ardehali A. The Role of Chemokine MIG/CXCL9 in T-Lymphocyte Proliferation and Cytokine Stimulation. American Transplant Congress, Washington, DC, 6/03
79. Whiting D, Banerji A, Chun S, Yun J, Gan X-H, Bonavida B, Ardehali A. Dual Properties of IP-10/CXCL10 in Allogeneic Responses. American Transplant Congress, Washington, DC, 6/03
80. Belperio JA, Keane MP, Burdick MD, Xue YY, Li KW, Ardehali A, Ross DJ, Strieter RM. The Role for KC/CXCL1 and MIP-2/CXCL2/3 in the Pathogenesis of Lung Transplantation Ischemia Reperfusion Injury. Federation of American Societies for Experimental Biology, 6/03
81. Whiting D, Hsieh G, Banerji A, Schnickel GT, Yun J, Bonavida B, Ardehali A. Chemokine MIG/CXCL9 Stimulates CD4 T Lymphocyte Proliferation and IFN Expression. ISHLT Annual Meeting. San Francisco, CA, 4/04
82. Schnickel GT, Whiting D, Ross D, Belperio J, Levine M, Shpiner R, Laks H, Beygui R, Ardehali A. Modified Reperfusion In Non-Standard Donor Lungs. ISHLT Annual Meeting. San Francisco, CA, 4/04
83. Ross DJ, Goldman MD, Strieter RM, Belperio JA, Ardehali A. Multi-Frequency Forced Oscillation Technique (FOT) For Assessment of Lung Allograft Function: A Pilot Study. ISHLT Annual Meeting. San Francisco, CA, 4/04
84. Whiting D, Hsieh GR, Schnickel GT, Banerji A, Shefizadeh A, Ardehali A. MIG/CXCL9 Induced T-Lymphocyte Proliferation is Independent of IL-2. American Transplant Congress, Boston, MA, 5/04
85. Mitropoulos FA, Laks H, Kermani R, Marelli D, Ardehali A, Plunkett M, Esmailian F, Odum J, Moriguchi J, Hamilton L, Jignesh P, Kobashigawa. Use of Donor Hearts with Left Ventricular Ejection Fraction < 50% for Transplantation. American Transplant Congress, Boston, MA, 5/04
86. Schnickel GT, Hsieh GR, Whiting D, Yun JJ, Yao W, Fishnein MC, Ardehali A. The Mechanism of CD8 Lymphocyte Function in Chronic Rejection of Heart Transplants. Western Thoracic Surgical Association, Maui, HI, 6/04

87. Schnickel GT, Ross D, Lackey S, Shefizadeh A, Ardehali A. Non-standard donor lungs: are they more prone to rejection? International Congress on Immunosuppression, San Diego, CA. 12/04
88. Hsieh GR, Schnickel GT, Garcia C, Shefizadeh A, Yao W, Ardehali A. The Synthetic Peptide D4F Attenuates Cardiac Allograft Vasculopathy. ISHLT Annual Meeting. Philadelphia, PA, 4/05
89. Schnickel GT, Ross D, Mitropoulos F, Lackey S, Shefizadeh A, Ardehali A. Clinical outcome following concomitant cardiac operation at the time of lung transplantation. ISHLT Annual Meeting. Philadelphia, PA, 4/05
90. Schnickel GT, Ross D, Lackey S, Shefizadeh A, Ardehali A. Non-standard donor lungs: are they more prone to rejection? ISHLT Annual Meeting. Philadelphia, PA, 4/05
91. Schnickel GT, Ross DR, Shefizadeh A, Laks HL, Beygui R, Lynch J, Ardehali A. Modified Reperfusion in Clinical Lung Transplantation: 100 consecutive cases. American Association for Thoracic Surgery, San Francisco, CA, 4/05
92. Schnickel GT, Hsieh GR, Garcia C, Shefizadeh A, Ardehali A. Cytoprotective Gene HO-1 and Chronic Rejection in Heart Transplantation. Western Thoracic Surgical Association, Sun Valley, Idaho, 6/06
93. Schnickel GT, Hsieh GR, Garcia C, Shefizadeh A, Fishbein MC, Ardehali A. Combined CXCR3 and CCR5 Blockade Attenuates Acute and Chronic Rejection. ISHLT Annual Meeting. Madrid, Spain 4/06
94. Schnickel GT, Hsieh GR, Garcia C, Shefizadeh A, Fishbein MC, Ardehali A. Focus on Inflammation and Oxidation: A New Approach to Management of Cardiac Allograft Vasculopathy. ISHLT Annual Meeting. Madrid, Spain, 4/06
95. Schnickel GT, Hsieh GR, Murdock JE, Shefizadeh A, Ross D, Saggarr R, Ardehali A. A Contemporary Experience in Lung Transplantation for Idiopathic Pulmonary Fibrosis. ISHLT Annual Meeting. Madrid, Spain, 4/06
96. Hsieh GR, Schnickel GT, Garcia C, Shefizadeh A, Fishbein MC, Ardehali A. Chemokine Receptor Blockade with a Synthetic Non-Peptide Compound Attenuates Cardiac Allograft Vasculopathy. ISHLT Annual Meeting. Madrid, Spain, 4/06
97. Schnickel GT, Hsieh G, Garcia C, Shefizadeh A, Ardehali A. Simultaneous CXCR3 and CCR5 Blockade Prolongs Allograft Survival and Reduces T-Cell. World Transplant Congress, Boston, MA, 7/06

98. Schnickel GT, Hsieh G, Garcia C, Shefizadeh A, Ardehali A. Cytoprotective Gene HO-1 and Chronic Rejection in Heart Transplantation. World Transplant Congress, Boston, MA, 7/06
99. Bastani S, Schnickel GT, Ross DJ, Beygui R, Shefizadeh A, Saggarr R, Ardehali A. Modified Reperfusion in Clinical Lung Transplantation: The Result of 134 Consecutive Cases. Southern California American College of Surgeons, Santa Barbara, CA, 1/07
100. Bastani S, Schnickel G, Hsieh G, Garcia C, Fishbein M, Ardehali A. CXCR3 and CCR5 Blockade Prevents Acute Rejection via Induction of Regulatory CD4 Lymphocytes. ISHLT Annual Meeting. San Francisco, CA, 4/07
101. Bastani S, Schnickel GT, Ross DJ, Beygui R, Ardehali A. Lung Transplantation in Older Patients? American Association for Thoracic Surgery, Boston, MA, 5/07.
102. Kobashigawa J, Patel J, Kawano M, Wu G, Kittleson M, Kiyosaki K, Moriguchi J, Ardehali A. The Long Term Outcome Of Treated Presensitized Patients Who Undergo Heart Transplantation: Is It Successful? American Heart Association, 6/07
103. Ross D, Wallace W, Lynch J, Kubak B, Saggarr R, Ardehali A, Beygui R, Fishbein M. Early Surveillance Biopsies Detect Lung Allograft Rejection and Lymphocytic Bronchiolitis. ISHLT Annual Meeting. San Francisco, CA, 4/07
104. Ross D, Belperio J, Burdick M, Sharpiro S, Saggarr R, Zisman D, Lynch J, Ardehali A, Strieter R. Augmentation of Type 1 Immune Response Cytokines/Chemokines is Associated with Pulmonary Arterial Hypertension. ISHLT Annual Meeting. San Francisco, CA, 4/07
105. Ross D, Lynch J, Saggarr R, Kubak B, Belperio J, Beygui R, Wallace W, Fishbein M, Ardehali A. Efficacy of Combination Therapy with High Dosages of IVIG and Anti-CD25+ (Basiximab) for Acute Lung Allograft Rejection or Organizing Pneumonia: A Pilot Study. ISHLT Annual Meeting. San Francisco, CA, 4/07
106. Miller S, Kobashigawa J, Kittleson M, Patel J, Kawano M, Ardehali A. The Use of ECMO/Intra-Aortic Balloon Pump to Support Hemodynamics in Patients with Cardiogenic Shock Due to Severe Rejection. ISHLT Annual Meeting. San Francisco, CA, 4/07
107. Kobashigawa J, Chinakarn L, Patel J, Kawano M, Song H, Hamilton M, Kiyosaki K, Ardehali A. Outcome Of Combined Kidney And Redo Heart Transplant Recipients From A Single Center. American Heart Association, Orlando, FL, 11/07

108. Kobashigawa J, Kiyosaki K, Kubak B, Patel J, Kittleson M, Ardehali A. Successful Use Of Immune Monitoring (Cylex) In Heart Transplantation For Rejection And Infection Risk. American Heart Association, Orlando, FL, 11/07
109. Yang S, Cui G, Beygui R, Esmailian F, Ardehali A, Plunkett M, Laks H, Sen L. Up-Regulated Transforming Growth Factor- β 1 Co-Localized with Elastin Lamella in Aortic Wall Contributes to Thoracic Aortic Dissection. American Heart Association, Orlando, Florida, 11/07
110. Yang S, Cui G, Beygui R, Esmailian F, Ardehali A, Tang J, Plunkett M, Laks H, Sen L. Comparison of Transforming Growth Factor- β 1 Expression in Aortic Wall of Thoracic Aortic Aneurysm Versus Dissection. American Heart Association, Orlando, Florida, 11/07
111. Kittleson MM, Ankrom AK, Patel JK, Kawano MA, Ardehali A, Kobashigawa JA. Aliskiren: A New Anti-Renin Blood Pressure Medication Appears Safe and Effective in Heart Transplant Recipients. ISHLT Annual Meeting. Boston, MA, 04/08.
112. Kittleson MM, Song HS, Patel JK, Kawano MA, Patel D, Kiyosaki KK, Ardehali A, Kobashigawa JA. End-Stage Renal Disease After Heart Transplantation: The Benefits of Kidney Transplantation. ISHLT Annual Meeting. Boston, MA, 04/08.
113. Kittleson MM, Vaidya AS, Patel JK, Kawano MA, Ardehali A, Kobashigawa JK. Long-Term Risks Post Steroid Weaning: Not so Rosy After All. ISHLT Annual Meeting. Boston, MA, 04/08.
114. Itagaki B, Patel JK, Kittleson MM, Kawano MA, Ardehali A, Kobashigawa JA. The Innocence of Coronary Spasm after Heart Transplantation. ISHLT Annual Meeting. Boston, MA, 04/08.
115. Patel JK, Brown A, Kittleson MM, Kawano JC, Kawano MA, Kiyosaki KK, Ardehali A, Kobashigawa JA. Malignancy Risk in 2007 with Current Immunosuppression Regimens. ISHLT Annual Meeting. Boston, MA, 04/08.
116. Moriguchi J, Kown M, Plunkett M, Esmailian F, Jocson R, Hillel L, Marelli D, Beygui R, Davis S, Ardehali A, Patel J, Kobashigawa J. Improved Clinical Outcomes Using Bi-Ventricular Assist Devices as Bridges to Transplant in Critically Ill Patients. ISHLT Annual Meeting. Boston, MA, 04/08.
117. Patel JK, Simenhoff B, Kittleson MM, Kawano MA, Ardehali A, Kobashigawa JA. Making Sense of Immunosenescence in Older Heart Transplant Recipients. ISHLT Annual Meeting. Boston, MA, 04/08.

118. Vaidya VS, Yajnik MV, Heidenreich P, Kawano MA, Vaidya AS, Patel JK, Kittleson MM, Ankrom AK, Ardehali A, Kobashigawa JA. Comparison of Survival and Costs Between Transplantation and Medical Treatment of End Stage Heart Failure. ISHLT Annual Meeting. Boston, MA, 04/08.
119. Kobashigawa JA, Reed E, Sue E, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Ardehali A. Successfully Treated Pre-Transplant Sensitized Patients Have Favorable Post-Transplant Outcomes. ISHLT Annual Meeting. Boston, MA, 04/08.
120. Kobashigawa JA, Kiyosaki KK, Patel JK, Kittleson MM, Ardehali A. Success of Immune Monitoring with ImmuKnow (Cylex) to Assess Rejection/Infectious Risk in Heart Transplantation. ISHLT Annual Meeting. Boston, MA, 04/08.
121. Patel JK, Kawano JC, Kittleson MM, Duong U, Kawano MA, Ardehali A, Kobashigawa JA. First-Year Statin Resistant Hypercholesterolemia: A Cause for Concern in the Development of Cardiac Allograft Vasculopathy. ISHLT Annual Meeting. Boston, MA, 04/08.
122. Patel JK, Itagaki B, Ankrom A, Kawano M, Kiyosaki KK, Yajnik M, Ardehali A, Kobashigawa J. Hemodynamic Compromise Rejection: Does the Heart Biopsy Influence Outcome? ISHLT Annual Meeting. Boston, MA, 04/08.
123. Kittleson MM, Carr SA, Patel JK, Kawano MA, Kiyosaki KK, Ankrom AK, Ardehali A, Kobashigawa JA. Everolimus May Have Lower Adverse Effect Profile Compared to Sirolimus in Heart Transplant Patients. ISHLT Annual Meeting. Boston, MA, 04/08.
124. Kittleson MM, Kawano JC, Kawano MA, Patel JK, Yajnik MV, Kiyosaki KK, Ardehali A, Kobashigawa JA. Hypercholesterolemia in Heart Transplant Patients on Proliferation-Signal Inhibitors: Is Statin Therapy Effective? ISHLT Annual Meeting. Boston, MA, 04/08.
125. Marelli D, Kobashigawa JA, Moriguchi JD, Shuvayev I, Wong SY, Kahn T, Patel JK, Beygui R, Esmailian F, Laks H, Plunkett MD, Ardehali A. ECMO to Salvage Severe Cardiogenic Shock in Advanced Heart Failure and Transplantation. ISHLT Annual Meeting. Boston, MA, 04/08.
126. Marelli D, Kobashigawa JA, Hamilton MA, Noguchi E, Moriguchi JD, Patel JK, Laks H, Esmailian F, Beygui R, Plunkett MD, Ardehali A. Long Term Outcome of Heart Transplant in the Elderly. ISHLT Annual Meeting. Boston, MA, 04/08.
127. Marelli D, Kobashigawa J, Beygui R, Esmailian F, Laks H, Plunkett M, Ardehali A. Tricuspid Valve Regurgitation (TR) After Heart Transplantation Using the Bicaval Anastomosis Technique. ISHLT Annual Meeting. Boston, MA, 04/08.

128. Shino M, Weigt S, Saggar R, Reed E, Lynch 3rd JP, Belperio J, Ardehali A, Ross DJ. Using Immune Cell Function Assays to Assess the Risk of Infection and Rejection in Lung Transplant Patients. American Thoracic Society, Toronto, ONT, Canada, 05/08.
129. Reed E, Sue E, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Ardehali A. Successfully Treated Pre-Transplant Sensitized Patients Have Favorable Post-Transplant Outcomes. ISHLT Annual Meeting. Boston, MA, 04/08.
130. Weight S, Huang C, Kean MP, Xue YY, Palchevskiy V, Ardehali A, Gregson AL, Kubak B, Saggar R, Ross DJ, Lynch III JP, Elashoff RM, Belperio JA. The Impact of Aspergillus Infection on Survival and Bronchiolitis Obliterans Syndrome in Lung Transplantation. ISHLT Annual Meeting. Boston, MA, 04/08.
131. Saggar R, Ross DJ, Weigt SS, Saggar R, Elashoff D, Zisman DA, Ardehali A, Gregson AL, Kubak B, Shapiro S, Fishbein MC, Lai C, Lynch III JA, Belperio JA, Wallace WD. Bronchiolitis Obliterans and Pulmonary Hypertension: A Clinicopathologic Study. ISHLT Annual Meeting. Boston, MA, 04/08.
132. Bastani S, Bhatia R, Manasrah R, Belperio J, Fishbein MC, Ardehali A. Chemokine Receptor Blockade Induced Regulatory T Cells. ISHLT Annual Meeting. Boston, MA 04/08.
133. Kwon MH, Moriguchi JD, Plunkett MD, Ardehali A, Beygui RE, Marelli D, Jocson R, Laks H, Shemin RJ, Esmailian F. Impact of Age on Outcomes of Ventricular Assist Devices Utilized as Bridge to Cardiac Transplantation. ISHLT Annual Meeting. Boston, MA 04/08.
134. McCurry K, Jevanandam V, Mihaljevic T, Couper G, Elanwar M, Saleh H, Ardehali A. Prospective Multi-Center Safety and Effectiveness Evaluation of the Organ Care System Device for Cardiac Use (PROCEED). ISHLT Annual Meeting. Boston, MA 04/08.
135. Tang J, Cui G, Laks H, Yang S, Ardehali A, Esmailian F, Plunkett M, Beygui R, Marelli D, Len S. Upregulated Transforming Growth Factor- β 1 Expression and Distribution in Coronary Arterial Wall from Patients with Cardiac Allograft Vasculopathy Versus Ischemic Cardiomyopathy. ISHLT Annual Meeting. Boston, MA, 04/08.
136. Patel JK, Kawano JC, Kittleson MM, Duong U, Kawano MA, Ardehali A, Kobashigawa JA. First-Year Statin Resistant Hypercholesterolemia: A Cause for Concern in the Development of Cardiac Allograft Vasculopathy. ISHLT Annual Meeting. Boston, MA, 04/08.

137. Tsui S, Dhital K, Eisenring C, Ardehali A. Ex-Vivo Assessment of Donor Hearts with the OCS to Detect Hidden Pathologies. ISHLT Annual Meeting. Boston, MA, 04/08.
138. Sherman W, Bastani S, Bhatia R, Fishbein MC, Ardehali A. CD4+CD25+ Regulatory T-Cells and Cardiac Allograft Vasculopathy. ISHLT Annual Meeting. Paris, France, 04/09.
139. Hamed A, Tsui S, Huber J, Lin R, Poggio EC, Ardehali A. Serum Lactate Is a Highly Sensitive and Specific Predictor of Post Cardiac Transplant Outcomes Using the Organ Care System. ISHLT Annual Meeting. Paris, France, 04/09.
140. Ankrom A, Patel J, Shao E, Carr S, Kawano M, Kittleson M, Kiyosaki K, Moriguchi J, Ardehali A, Kobashigawa J. Obesity Confers Protection from Cardiac Allograft Vasculopathy? ISHLT Annual Meeting. Paris, France, 04/09.
141. Bastani S, Sherman W, Mahidhara RS, Ross D, Saggarr R, Lynch J, Zisman D, Belperio J, Ardehali A. Survival Benefit of Contemporary Lung Transplantation in Patients with IPF. ISHLT Annual Meeting. Paris, France, 04/09.
142. Rabkin DG, Bastani S, Mahidhara RS, Ross DJ, Saggarr R, Lynch JP, Hunter CT, Hamilton MA, Ardehali A. Survival of Lung Transplant Recipients with Concomitant Myocardial Revascularization. ISHLT Annual Meeting. Paris, France, 04/09.
143. Kiyosaki K, Kobashigawa J, Reed E, Moriguchi J, Kawano M, Ankrom A, Patel J, Kittleson M, Shao E, Ardehali A. The Outcome of Treatment of 100% PRAs in Heart Failure Patients Awaiting Heart Transplantation. ISHLT Annual Meeting. Paris, France, 04/09.
144. Kawano M, Kobashigawa J, Kiyosaki K, Ankrom A, Patel J, Kittleson M, Reed E, Ardehali A. Outcome of Retrospective Positive Donor Specific Crossmatch after Heart Transplantation: Are They Doomed? ISHLT Annual Meeting. Paris, France, 04/09.
145. Shao E, Kawano M, Moradzadeh N, Ankrom A, Kiyosaki K, Patel J, Kittleson M, Moriguchi J, Ardehali A, Kobashigawa J. Right Ventricular Dysfunction Immediately Post Transplant – A Marker for Poor Outcome? ISHLT Annual Meeting. Paris, France, 04/09.
146. Sohrabian S, Kawano M, Kiyosaki K, Ankrom A, Patel J, Moriguchi J, Kittleson M, Ardehali A, Kobashigawa J. Spare Me the Renal Sparing Protocol – Poor Long Term Outcomes. ISHLT Annual Meeting. Paris, France, 04/09.

147. Kim BJ, Kiyosaki KK, Shao E, Patel JK, Kittleson M, Kawano MA, Ankrom A, Moriguchi J, Ardehali A, Kobashigawa JA. Early Permanent Pacemaker after Heart Transplantation Is a Surrogate Marker for Poor Outcome: Possible Immune Mechanisms. ISHLT Annual Meeting. Paris, France, 04/09.
148. Patel J, Kawano MA, Kiyosaki KK, Ankrom A, Kittleson M, Moriguchi J, Ardehali A, Kobashigawa J. When Is Too Old, Too Old for Redo Heart Transplantation? ISHLT Annual Meeting. Paris, France, 04/09.
149. Shao E, Kawano M, Kiyosaki K, Patel J, Kittleson M, Moriguchi J, Ardehali A, Kobashigawa J. Late Rapidly Progressive Cardiac Allograft Vasculopathy Is Associated with Poor Outcome. ISHLT Annual Meeting. Paris, France, 04/09.
150. Sherman W, Bastani S, Schnickel GT, Hsieh GR, Bhatia R, Fishbein MC, Ardehali A. CXCR3 and CCR5 in Acute and Chronic Rejection. ISHLT Annual Meeting. Paris, France, 04/09.
151. Lo K, Kiyosaki K, Kobashigawa J, Kawano M, Ankrom A, Kittleson M, Shao E, Moriguchi J, Patel J, Ardehali A. Low Peak Oxygen Consumption by Cardiopulmonary Stress Testing after Heart Transplantation Predicts Poor Outcome. ISHLT Annual Meeting. Paris, France, 04/09.
152. Moreno E, Valleca A, Patel J, Kawano M, Lockhart D, Montgomery S, Burch C, Rangel L, Kao T, Koyosaki K, Wong S, Ankrom A, Ventura L, Kittleson M, Moriguchi J, Shao E, Ardehali A, Kobashigawa JA. Does High Risk Status Identified by Pre-Transplant Social Worker and Psychiatric Evaluation Predict outcome after Heart Transplant? ISHLT Annual Meeting. Paris, France, 04/09.
153. Patel J, Kawano M, Kiyosaki K, Shao E, Ankrom A, Kittleson M, Moriguchi J, Ardehali A, Kobashigawa J. Addressing the Myth of Elevated Bilirubin as a Contraindication to Heart Transplantation. ISHLT Annual Meeting. Paris, France, 04/09.
154. Shao E, Kawano M, Patel J, Kittleson M, Ankrom A, Kiyosaki K, Moriguchi J, Ardehali A, Kobashigawa J. The Problem of Rejection in Redo Heart Transplant Recipients. ISHLT Annual Meeting. Paris, France, 04/09.
155. Patel J, Kubak B, Kawano M, Ankrom A, Yajnik M, Kiyosaki K, Kittleson M, Moriguchi J, Ardehali A, Kobashigawa J. The Efficacy of Shorter Duration CMV Prophylaxis after Heart Transplantation. ISHLT Annual Meeting. Paris, France, 04/09.
156. Kiyosaki K, Kobashigawa J, Patel J, Patel J, Ankrom A, Kittleson M, Kawano M, Moriguchi J, Shao E, Ardehali A. The Benefit of Immune Monitoring (Cylex): A

- Review of 864 Immune Monitoring Assays in Heart Transplantation. ISHLT Annual Meeting. Paris, France, 04/09.
157. Patel J, Shao E, Patel J, Kawano M, Kiyosaki K, Ankrom A, Kittleson M, Moriguchi J, Ardehali A, Kobashigawa J. Pre-Transplant FEV1/FVC but Not FEV1 Along by Pulmonary Function Testing Predicts Poor Outcome after Heart Transplantation: The Bane of COPD. ISHLT Annual Meeting. Paris, France, 04/09.
 158. Hong EA, Shemin R, Ardehali A, Esmailian F, Kittleson M, Patel J, Laks H, Jocson R, Kobashigawa J, Moriguchi J. Does Treatment of Sensitized VAD Patients Improved Post Heart Transplant Outcomes? ISHLT Annual Meeting. Paris, France, 04/09.
 159. Saggar R, Saggar R, Khanna D, Furst DE, Park GS, Belperio JA, Weigt S, Zisman DA, Shapiro S, Hunter C, Clements PJ, Lynch JP, Ardehali A, Ross DJ. Systemic Sclerosis and Lung Transplantation: A Single Center Experience. ISHLT Annual Meeting. Paris, France, 04/09.
 160. Patel J, Kiyosaki K, Kubak B, Kawano M, Patel J, Ankrom A, Kittleson M, Shao E, Moriguchi J, Ardehali A, Kobashigawa J. Surreptitious Aspergillus Colonization Is Not Associated with Poor Outcome While on Suppressive Azole Therapy. ISHLT Annual Meeting. Paris, France, 04/09.
 161. Weigt SS, Tseng C-H, Huang C, Ross DJ, Saggar R, Saggar R, Lynch JP, Gregson A, Kubak BM, Ardehali A, Elashoff RM, Belperio JA. The Impact of Aspergillus Colonization on Acute Rejection and Lymphocytic Bronchiolitis in Lung Transplant Patients. ISHLT Annual Meeting. Paris, France, 04/09.
 162. Saggar R, Belperio J, Saggar R, Hunter C, Weigt SS, Lynch JP, Zisman DA, Gregson A, Kubak B, Lackey S, Ross DJ, Ardehali A. Intraoperative Versus Postoperative Rabbit Anti-Thymoglobulin Globulin Induction for Bilateral Lung Transplantation: A Single Center Randomized Double Blind Placebo Controlled Trial. ISHLT Annual Meeting. Paris, France, 04/09.
 163. Kwon, M, Ankrom A, Ardehali A, Kawano M, Kittleson M, Kiyosaki K, Kobashigawa J. Oversizing Donor Cardiac Allografts for Patients with Pulmonary Hypertension May Not Be Necessary. ISHLT Annual Meeting. Paris, France, 04/09.
 164. Kobashigawa, J, Patel J, Kiyosaki K, Shao E, Ankrom A, Arbit B, Hage A, Kittleson M, Ardehali A. The Impact of Average First Year Heart Rate on Outcomes after Heart Transplantation: Does It Make a Difference? American Transplant Congress, Boston, MA, 05/09.

165. Koyosaki K, Kobashigawa J, Patel J, Kittleson M, Kawano M, Hage A, Ardehali A. Protocol vs. Symptom Directed Endomyocardial Biopsies after Heart Transplantation: Are Protocol Biopsies Necessary? American Transplant Congress, Boston, MA, 05/09.
166. Patel J, Kobashigawa J, Kawano M, Kiyosaki K, Patel J, Ankrom A, Shao E, Hage A, Kittleson M, Ardehali A. Pulmonary Embolism 6 Months before Heart Transplant Does Not Appear To Be a Risk for Post Transplant Emypema or Poor Outcome. American Transplant Congress, Boston, MA, 05/09.
167. Patel J, Kobashigawa, J, Kawano M, Kiyosaki K, Ankrom A, Kittleson M, Moriguchi J, Ardehali A. Clinical Effectiveness of Desensitization Therapy in Sensitized Patients Awaiting Heart Transplant. American Heart Association, Orlando, FL, 11/09
168. Patel J, Kittleson M, Kubak B, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Development of Cytomegalovirus (CMV) Infection during Ongoing Valganciclovir Therapy. ISHLT Annual Meeting. Chicago, IL, 04/10.
169. Montgomery S, Kawano M, Lockhart D, Velleca A, Burch C, Patel J, Davis S, Kittleson M, Moriguchi J, Ardehali A, Kobashigawa J. Does Race Mismatch Have an Impact on Outcome after Heart Transplantation? ISHLT Annual Meeting. Chicago, IL, 04/10.
170. Patel J, Kittleson M, Azarbal A, Hage A, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Does a Normal Angiogram Further from Heart Transplantation Confer Less Chance To Develop CAV? Should We Still Do Annual Angiograms Late after Transplantation? ISHLT Annual Meeting. Chicago, IL, 04/10.
171. Patel J, Kittleson M, Share M, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Persistent Pulmonary Hypertension in Heart Transplant Patients: Is This a Recipe for Long-Term Failure? ISHLT Annual Meeting. Chicago, IL, 04/10.
172. Sherman W, Kobashigawa J, Hamilton M, Gjertson D, Gomez Abraham J, Laks H, Ardehali A. Does Listing Status Affect Cost of Heart Transplantation? ISHLT Annual Meeting. Chicago, IL, 04/10.
173. Velleca A, Burch C, Montgomery S, Lockhart D, Patel J, Kittleson M, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. The Threat of Medication Miscommunication in Non-English Speaking Heart Transplant Recipients. ISHLT Annual Meeting. Chicago, IL, 04/10.
174. Kittleson M, Patel J, Moriguchi J, Kawano M, Patel K, Davis S, Hage A, Hamilton M, Ardehali A, Kobashigawa J. Heart Transplant Rejection with Cardiogenic

- Shock Supported with Extracorporeal Membrane Oxygenation (ECMO): Outcome from a Single Center Experience. ISHLT Annual Meeting. Chicago, IL, 04/10.
175. Burch C, Amegatcher A, Patel J, Kittleson M, Kawano M, Davis S, Goldstein Z, Moriguchi J, Ardehali A, Kobashigawa J. Transition of Pediatric Heart Transplant Patients to the Adult Heart Transplant Program: Are They Doomed To Be Rejected? ISHLT Annual Meeting. Chicago, IL, 04/10.
 176. Kittleson M, Patel J, Reed E, Zhang Q, Cecka M, Stimpson E, Velleca A, Burch C, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Does MFI Quantitation of Circulating Antibodies Correlate with Positive Cytotoxicity? ISHLT Annual Meeting. Chicago, IL, 04/10.
 177. Patel J, Kittleson M, Reed E, Aguas G, Kawano M, Davis S, Burch C, Velleca A, Stimpson E, Moriguchi J, Ardehali A, Kobashigawa J. The Importance of Anti-HLA DQ Antibodies as a Risk Factor for the Development of Transplant Coronary Artery Disease (TCAD) after Heart Transplantation. ISHLT Annual Meeting. Chicago, IL, 04/10.
 178. Lai C, Patel J, Fishbein M, Kittleson M, Share M, Davis S, Kawano M, Moriguchi J, Ardehali A, Kobashigawa J. C4d in Heart Transplant Biopsies Does Not Appear to Represent Poor Outcome. ISHLT Annual Meeting. Chicago, IL, 04/10.
 179. Patel J, Kittleson M, Zhang Q, Reed E, Kawano M, Davis S, Cecka M, Burch C, Velleca A, Stimpson E, Moriguchi J, Ardehali A, Kobashigawa J. Are Circulating Antibodies Necessary To Make a Diagnosis of Antibody-Mediated Rejection? ISHLT Annual Meeting. Chicago, IL, 04/10.
 180. Lockhart D, Doering L, Burch C, Montgomery S, Velleca A, Patel J, Kittleson M, Davis S, Kawano M, Goldstein Z, Morazadeh A, Moriguchi J, Ardehali A, Kobashigawa J. Are Recipients from Heart Donors Listed as Homeless at Increased Risk for Poor Outcome after Heart Transplantation? ISHLT Annual Meeting. Chicago, IL, 04/10.
 181. Kittleson M, Patel J, Azarbal B, Moriguchi J, Kawano M, Davis S, Hage A, Ardehali A, Kobashigawa J. First Angioplasty Does Not Appear to Alter Outcome in heart Transplant Patients with Newly Diagnosed Transplant Coronary Artery Disease. ISHLT Annual Meeting. Chicago, IL, 04/10.
 182. Patel J, Kittleson M, Kubk B, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Asymptomatic Positive CMV Serology Is Associated with Increase Risk for the Development of Transplant Coronary Artery Disease (TCAD): Who needs Symptoms? ISHLT Annual Meeting. Chicago, IL, 04/10.

183. Sherman W, Rabkin D, Ross D, Saggar R, Lynch JP, Gjertson D, Hamilton M, Ardehali A. Should Patients with Coronary Artery Disease Undergo Lung Transplantation? ISHLT Annual Meeting. Chicago, IL, 04/10.
184. Kawano M, Kittleson M, Fishbein M, Lai C, Patel J, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Review of 12,703 Endomyocardial Biopsies: The Truth of Quilty Lesions in the Cyclosporine and Tacrolimus Era. ISHLT Annual Meeting. Chicago, IL, 04/10.
185. Kittleson M, Patel J, Moriguchi J, Moradzadeh A, Kawano M, Davis S, Ardehali A, Kobashigawa J. The Adverse Effects of Sirolimus in Heart Transplant Patients: Is It Worth it? ISHLT Annual Meeting. Chicago, IL, 04/10.
186. Kittleson M, Patel J, Reed E, Gjertson D, Kawano M, Davis S, Burch C, Velleca A, Stimpson E, Moriguchi J, Ardehali A, Kobashigawa J. Accommodation after Heart Transplantation: Does It Exist? ISHLT Annual Meeting. Chicago, IL, 04/10.
187. Patel J, Kittleson M, Reed E, Zhang Q, Rajalingam R, Velleca A, Stimpson E, Burch C, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. The Effectiveness of a Standardized Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies (cPRA) in Sensitized Heart Transplant Candidates: Does It Make Sense To Desensitize? ISHLT Annual Meeting. Chicago, IL, 04/10.
188. Kawano M, Patel J, Kittleson M, Reed E, Gjertson D, Cecka M, Velleca A, Stimpson E, Burch C, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. The Incidence and Outcome of Sensitization in Patients Awaiting Re-do Heart Transplantation. ISHLT Annual Meeting. Chicago, IL, 04/10.
189. Moreno E, Velleca A, Burch C, Patel J, Kittleson M, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Pre-Transplant Smoking in Heart Transplant Patients: A Marker for Long Term Outcome? ISHLT Annual Meeting. Chicago, IL, 04/10.
190. Kwon M, Moriguchi J, Kittleson M, Patel J, Kawano M, Davis S, Reed E, Burch C, Velleca A, Stimpson E, Ardehali A, Kobashigawa J. Transplantation on Heartmate II Axial Flow Assist Devices. ISHLT Annual Meeting. Chicago, IL, 04/10.
191. Shemin R, Patel J, Ardehali A, Kittleson M, Kawano M, Davis S, Moriguchi J, Kobashigawa J. Gender Mismatch in Non-induction/Triple-Drug Regimens: Poor 10-Year Outcomes. ISHLT Annual Meeting. Chicago, IL, 04/10.
192. Kittleson M, Moriguchi J, Kwon M, Reed E, Davis S, Kawano M, Burch C, Velleca A, Stimpson E, Patel J, Ardehali A, Kobashigawa J. Highly Sensitized Patients

- on VAD Support Awaiting Heart Transplant on a Ventricular Assist Device (VAD) Appear To Have a Less Robust Immune Response compared to Non-VAD Patients. ISHLT Annual Meeting. Chicago, IL, 04/10.
193. Patel J, Kittleson M, Davis S, Kawano M, Moriguchi J, Ardehali A, Kobashigawa J. 10-Year Follow-up of Hepatitis C Donor Hearts in Triple-Drug Immunosuppression: The Final Nail in the Coffin. American Transplant Congress, San Diego, CA, 05/10.
 194. Kittleson M, Patel J, Kawano M, Davis S, Share M, Moriguchi J, Hamilton M, Ardehali A, Kobashigawa J. Safety and Efficacy of Sildenafil in the 1st Year after Heart Transplantation for Pulmonary Hypertension. American Transplant Congress, San Diego, CA, 05/10.
 195. Azarbal B, Patel J, Kittleson M, Davis S, Kawano M, Moradzadeh A, Goldstein Z, Moriguchi J, Ardehali A, Kobashigawa J. Treadmill Nuclear Stress Testing Appears Effective to Detect Coronary Ischemia in Heart Transplant Patients with Established Transplant Coronary Artery Disease. American Transplant Congress, San Diego, CA, 05/10.
 196. Kawano M, Patel J, Kittleson M, Hamilton M, Hage A, Moradzadeh A, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. The Effects of Donor Height in Heart Transplant Patients on Triple Drug Immunosuppression. American Transplant Congress, San Diego, CA 05/10.
 197. Patel J, Kittleson M, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Are Quilty B Lesions in Heart Transplant Biopsies in Patients on Tacrolimus Immunosuppression Harbingers of Rejection? A Review of 3651 Endomyocardial Biopsies. American Transplant Congress, San Diego, CA 05/10.
 198. Davis S, Patel J, Kittleson M, Kawano M, Moriguchi J, Hamilton M, Ardehali A, Kobashigawa J. Potential Immunomodulatory Effects of Granulocyte Colony Stimulating Factor (GCSF) in Heart Transplant Patients. American Transplant Congress, San Diego, CA 05/10.
 199. Kittleson M, Patel J, Moriguchi J, Moradzadeh A, Kawano M, Davis S, Ardehali A, Kobashigawa J. Splenectomy Prior to Heart Transplantation Does Not Affect Risk for Rejection and/or Infection after Heart Transplantation in Patients on Triple Drug Immunosuppression. American Transplant Congress, San Diego, CA, 05/10.
 200. Jaime Moriguchi, Stephanie Davis, Rhodora Jocson, Fardad Esmailian, Abbas Ardehali, Hillel Laks, Murray Kwon, Michelle Kittleson, Jon Kobashigawa, Jignesh Patel, Daniel Marelli, Mark Plunkett, Ramin Beygui, Richard Shemin. Successful use of a pneumatic biventricular assist device as a bridge to

- transplantation in cardiogenic shock. ISHLT Annual Meeting. San Diego, CA, 4/11.
201. Michelle M. Kittleson, Richard Shemin, Jignesh K. Patel, Abbas Ardehali, Matt Kawano, Stephanie Davis, Jaime D. Moriguchi, Jon A. Kobashigawa. Donor-recipient sex mismatch portends poor 10-year outcomes in a single-center experience. ISHLT Annual Meeting. San Diego, CA, 4/11.
 202. Hsuanwen C. Huang, S. Samuel Weigt, Ariss Derhovanessian, Vyacheslav Palchevskiy, Abbas Ardehali, Rajan Sagggar, Rajeev Sagggar, Bernard Kubak, Aric Gregson, David J. Ross, Joseph P. Lynch III, Robert Elashoff, John A. Belperio. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. ISHLT Annual Meeting. San Diego, CA, 4/11.
 203. D.J. Ross, K. Navab, B.J. Van Lenten, D.E. Furst, P.J. Clements, A. Ardehali, J. Aboulhosn, A.M. Fogelman, M. Navab, Pro-Inflammatory HDL in Idiopathic and Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (PAH) Is Improved Ex Vivo by an Apolipoprotein-AI Mimetic Peptide: A Potential "Target" for Therapies. ISHLT Annual Meeting. San Diego, CA, 4/11.
 204. Kwon MH, Zhang JQ, Abrahamyan A, Zhang ZK, Gjertson DW, Ardehali A, Kobashigawa J, Shemin R, Reed EF. Characterization of Ventricular Assist Device Mediated Sensitization in the Bridge to Heart Transplant Patient. American Heart Association Basic Cardiovascular Sciences 2011 Scientific Sessions, New Orleans, Louisiana, 7/11.
 205. W. Sherman, A. Chaudhry, D. Klarin, D. Ross, J. Belperio, J.P. Lynch, R. Sagggar, C. Hunter, M. Kwon, D. Gjertson, A. Ardehali. Does Age Matter in Lung Transplantation? ISHLT Annual Meeting. Prague, Czech Republic, 4/12.
 206. Michael Y. Shino, S. Samuel Weigt, Rajan Sagggar, David Elashoff, Ariss Derhovanessian, Aric L. Gregson, Rajeev Sagggar, Elaine F. Reed, Bernard M. Kubak, Joseph P. Lynch III, John A. Belperio, Abbas Ardehali, David J. Ross. Usefulness of immune monitoring in lung transplantation using adenosine triphosphate production in activated lymphocytes. ISHLT Annual Meeting. Prague, Czech Republic, 4/12.
 207. David J. Ross, , Robert M. Strieter, , Michael C. Fishbein, , Abbas Ardehali, , John A. Belperio, , Type I immune response cytokine-chemokine cascade is associated with pulmonary arterial hypertension. ISHLT Annual Meeting. Prague, Czech Republic, 4/12.
 208. W. Sherman, A. Chaudhry, D. Klarin, D. Ross, J. Belperio, J.P. Lynch, R. Sagggar, C. Hunter, M. Kwon, D. Gjertson, A. Ardehali, Does Age Matter in Lung Transplantation? ISHLT Annual Meeting. Prague, Czech Republic, 4/12.

209. T. Khuu, R. Cheng, A.S. Baas, D. Cruz, A. Nsair, B. Kubak, A. Ardehali, R.J. Shemin, A. Hickey, M.C. Deng, Low Absolute Lymphocyte Count at Six Months Post-Heart Transplantation Predictive of Late-Onset CMV. ISHLT Annual Meeting. Prague, Czech Republic, 4/12.
210. G. Warnecke, A. Haverich, G. Massard, N. Santelmo, F. Rea, C. Knosalla, R. Hetzer, G. Leseche, A. Ardehali, A.R. Simon, J. Kukreja, K. McCurrey. The INSPIRE International Lung Trial with the Organ Care System Technology (OCS™). ISHLT Annual Meeting. Prague, Czech Republic, 4/12.
211. S.S. Weigt, X. Wang, C.-H. Tseng, A. Derhovanessian, A. Gregson, R. Saggarr, D.J. Ross, A. Ardehali, J.P. Lynch III, R.M. Elashoff, J.A. Belperio. The Fibroproliferative Chemokine, Eotaxin/CCL11, Is Upregulated in Lung Transplant Recipients Colonized with Aspergillus – A Link to BOS? ISHLT Annual Meeting. Prague, Czech Republic, 4/12.
212. A. Yadlapati, J. Aboulhosn, J. Belpario, D. Ross, A. Ardehali, R. Saggarr. Pre-Operative Cardiac Variables and Clinical Outcomes in Patients with Bilateral Lung Transplants. ISHLT Annual Meeting. Prague, Czech Republic, 4/12.
213. Shroyer, A; Baltz, J; Hattler, B; Gupta, S; Ardehali, A; Collins, J F.; Grover, F; Bakaeen, F G, Ebrahimi R. The Effect of Post-Coronary Artery Bypass Surgery Clopidogrel use on One-Year Clinical Outcomes – A Sub-Analysis of the ROOBY Trial, AVAS 37th Annual Meeting, Milwaukee, WI, 4/13.
214. Ross DJ, Hough G, Hama S, Aboulhosn J, Belperio JA, Saggarr R, Van Lenten BJ, Ardehali A, Eghbali M, Reddy S, Fogelman AM, Navab M. Pro-Inflammatory HDL Result from Altered HDL Oxidized Lipid Mediators in Both Idiopathic and Associated Types of Pulmonary Arterial Hypertension. ISHLT Annual Meeting. Montreal, Canada, 4/13.
215. F. Esmailian, J.A. Kobashigawa, Y. Naka, D. Mancini, E. Soltesz, E. Hsich, M. Camacho, D. Baran, J. Madsen, P. LePrince, M. Deng, A. Ardehali. The PROCEED II International Heart Transplant Trial with the Organ Care System Technology (OCS). ISHLT Annual Meeting. Montreal, Canada, 4/13.
216. G. Warnecke, B. Weigmann, D. Van Raeonck, G. Massard, N. Santelmo, P.-E. Falcoz, A. Olland, G. Leseche, H. Mal, P. Thomas, F. Rea, G. Marulli, C. Knosalla, R. Hetzer, A. Ardehali, J. Kukreja, C. Bermudez, F.J. Moradiellos, A. Varela, K. Dhital, J. Nagendran, K. McCurry, A. Haverich. The INSPIRE International Lung Trial with the Organ Care System Technology (OCS™). ISHLT Annual Meeting. Montreal, Canada, 4/13.
217. A. Der Hovanessian, V. Palchevskiy, S.S. Weigt, M.Y. Shino, A.L. Gregson, B.M. Kubak, J.P. Lynch, R. Saggarr, D.J. Ross, A. Ardehali, R.M. Elashoff, J.A. Belperio. The CCL2/CCR2 Axis in Primary Graft Dysfunction and Bronchiolitis

- Obliterans Syndrome Following Lung Transplantation. ISHLT Annual Meeting. Montreal, Canada, 4/13.
218. T. Khuu, R.K. Cheng, M. Cadeiras, M. Allareddy, A. Baas, D. Cruz, E. Depasquale, A. Hickey, B. Kubak, A. Nsair, C. Holt, M.C. Fishbein, M.H. Kwon, A. Ardehali, R.J. Shemin, E.F. Reed, M.C. Deng. Comparing Bortezomib to Traditional Therapies for Antibody-Mediated Rejection (AMR): Out with the Old? ISHLT Annual Meeting. Montreal, Canada, 4/13.
 219. E.C. DePasquale, R.K. Cheng, A. Ardehali, A. Baas, M. Cadeiras, D. Cruz, T. Khuu, A. Nsair, M.C. Deng. Outcomes in Patients with Ischemic Cardiomyopathy (ICM) Post-Heart Transplant (HT) by Era. ISHLT Annual Meeting. Montreal, Canada, 4/13.
 220. T. Khuu, M. Cadeiras, N. Wisniewski, M. Allareddy, A. Baas, R.K. Cheng, D. Cruz, E. Depasquale, A. Hickey, B. Kubak, A. Nsair, R. Rajalingam, W. Khuu, A. Ren, C. Holt, M.C. Fishbein, M.H. Kwon, A. Ardehali, R.J. Shemin, E.F. Reed, M.C. Deng. Reduced HLA Class II Antibody Response to Proteasome Inhibition. ISHLT Annual Meeting. Montreal, Canada, 4/13.
 221. E.C. DePasquale, R.K. Cheng, A. Ardehali, A. Baas, M. Cadeiras, D. Cruz, T. Khuu, A. Nsair, D.L. Jacoby, M.C. Deng. Outcomes of Adult Heart (HT) Versus Heart-Kidney (H+K) Transplant: Influence of CKD (Chronic Kidney Disease) Stage. ISHLT Annual Meeting. Montreal, Canada, 4/13.
 222. M. Deng, E. Soltesz, E. Hsich, Y. Naka, D. Mancini, F. Esmailian, J. Kobashigawa, M. Camacho, D. Baran, J. Madsen, P. LePrince, A. Ardehali. Ex-Vivo Perfusion of Human Donor Hearts Reduces Cold Ischemia Time. ISHLT Annual Meeting. Montreal, Canada, 4/13.
 223. M. Deng, E. Soltesz, E. Hsich, Y. Naka, D. Mancini, F. Esmailian, J. Kobashigawa, M. Camacho, D. Baran, J. Madsen, P. LePrince, A. Ardehali. Is Lactate Level during Warm Perfusion a Predictor for Post Transplant Outcomes? ISHLT Annual Meeting. Montreal, Canada, 4/13.
 224. E.C. DePasquale, R.K. Cheng, A. Ardehali, A. Baas, M. Cadeiras, D. Cruz, T. Khuu, A. Nsair, D.L. Jacoby, M.C. Deng. Influence of Pre-Transplant Chronic Kidney Disease (CKD) on Adult Heart Transplant (HT) Outcomes. ISHLT Annual Meeting. Montreal, Canada, 4/13.
 225. E.C. DePasquale, R.K. Cheng, A. Ardehali, A. Baas, M. Cadeiras, D. Cruz, T. Khuu, A. Nsair, M. Deng. Does Gender Influence Survival of Heart Transplant (HT) Recipients Bridged with LVAD Support? ISHLT Annual Meeting. Montreal, Canada, 4/13.

226. S.S. Weigt, X. Wang, S. Numnez, A. Derhovanesian, M.Y. Shino, A. Gregson, J.P. Lynch III, R. Saggari, D.J. Ross, A. Ardehali, R. Elashoff, J.A. Belperio. YKL-40 Production Is Increased in the Lung during Aspergillus Colonization and BOS after Lung Transplantation. ISHLT Annual Meeting. Montreal, Canada, 4/13.
227. E. Larson, M. Girgis, A. Lin, M. Russell, A. Ardehali, D. Ross, J. Yoo. Diverticulitis Occurs Early After Lung Transplantation. Academic Surgical Congress 2014, San Diego, CA, 2/14.
228. D Van Raelonck, G. Warnecke, J. Kukreja, M. Smith, G. Loor, J. Garcia, M. Hertz, J. Madsen, A. Haverich, A. Ardehali. The EXPAND Lung International Trial to Evaluate the Safety and Effectiveness of the Portable Organ Care System (OCSTM) Lung for Recruiting, Preserving and Assessing Expanded Criteria Donor Lungs for Transplantation. ISHLT Annual Meeting. San Diego, CA 4/14.
229. Q. Zhang, J. McNamara, M. Cadeiras, T. Khuu, A. Baas, E.C. DePasquale, N. Halnon, G. Perens, J.A. Carlos, A. Nsair, R. Shemin, K. Murray, A. Ardehali, M. Deng, E.F. Reed. Incidence and Importance of Donor-Specific HLA Antibody in Heart Transplant Recipients. ISHLT Annual Meeting. San Diego, CA 4/14.
230. E.C. DePasquale, D. Ross, A. Ardehali. Lung Transplantation in Scleroderma. ISHLT Annual Meeting. San Diego, CA 4/14.
231. A. DerHovanesian, N. Li, M. Shino, D.M. Sayah, A.L. Gregson, J.P. Lynch III, R. Saggari, A. Ardehali, D.J. Ross, R.M. Elashoff, S. Weigt. Defining Clinically Relevant CLAD Phenotypes in Bilateral and Single Lung Transplant Recipients. ISHLT Annual Meeting. San Diego, CA 4/14.
232. E.C. DePasquale, R.P. Vivo, A. Nsair, M. Cadeiras, D. Cruz, R. Ardehali, A.S. Baas, M.C. Deng, G.C. Fonarow, L.C. Reardon, A. Ardehali. Comparison of Survival between Pediatric and Adult Patients after Biventricular Assist Device Implantation: Analysis of the UNOS Database. ISHLT Annual Meeting. San Diego, CA 4/14.
233. E.C. DePasquale, R.K. Cheng, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, T. Khuu, M. Deng, H. Laks, A. Ardehali. Cardiac Retransplantation: How Far Have We Come? ISHLT Annual Meeting. San Diego, CA 4/14.
234. G. Warnecke, D. Van Raelonck, G. Massard, F. Rea, M. Smith, J. Kukreja, F. De Robertis, K. Shital, J. Nagendran, J. Moradiellos, C. Bermudez, S. Tsui, G. Leseche, C. Knosalla, K. McCurry, P. Thomas, G. Loor, J. Garcia, I. Wang, M. Avsar, I. Tudorache, C. Kuhn, B. Wiegmann, W. Sommer, N. Santelmo, P. Falcoz, A. Olland, M. Schiavon, G. Marulli, G. Di Gregorio, A. Simon, R. Hetzer, A. Varela, J. Madsen, M. Hertz, A. Haverich, A. Ardehali. The INSPIRE Lung International Trial Evaluating the Impact of Portable Ex-vivo Perfusion Using the

- Organ Care System (OCSTM) Lung Technology on Routine Lung Transplant Outcomes. ISHLT Annual Meeting. San Diego, CA 4/14.
235. A. Nsair, L. Reardon, M. Deng, A. Ardehali, E.C. DePasquale. Outcomes of Heart Transplant (HT) Recipients Bridged with BIVAD (BiVentricular Assist Device). ISHLT Annual Meeting. San Diego, CA 4/14.
236. A. Ardehali, D. Mancini, Y. Naka, J. Kobashigawa, F. Esmailian, E. Hsich, E. Soltesz, M. Deng. Heart Transplantation After Ex-Vivo Perfusion of the Donor Hearts: Does it Affect Inotropic Use and Hospital Stay? ISHLT Annual Meeting. San Diego, CA 4/14.
237. A. Ardehali, F. Esmailian, M. Deng, E. Soltesz, E. Hsich, Y. Naka, D. Mancini, M. Camacho, D. Baran, M. Zucker, P. Leprince, J. Madsen, S. Tsui, A. Simon, U. Livi, G. Buzzi, J. Kobashigawa. The PROCEED II International Heart Transplant Trial with the Organ Care System (OCSTM) Technology. ISHLT Annual Meeting. San Diego, CA 4/14.
238. E.C. DePasquale, A. Nsair, L. Reardon, A. Ardehali, M. Deng. Influence of MELD (Model of End-Stage Liver Disease) _XI (eXcluding INR) on Post-Heart Transplant (HT) Outcomes. ISHLT Annual Meeting. San Diego, CA 4/14.
239. E.C. DePasquale, A. Nsair, M. Gayheart, L. Reardon, M. Deng, A. Ardehali. Outcomes of Heart vs Heart-Liver Transplantation: UNOS Registry Analysis. ISHLT Annual Meeting. San Diego, CA 4/14.
240. D.J. Ross, A. Ardehali, J. Belperio, A. DerHovanessian, S.S. Weigt, D. Sayah, J.P. Lynch III, R. Sagggar, M. Shino, M. Jacquet, B. Kubak, T. Ganz. Serum Hepcidin Antimicrobial Peptide Levels Predict Infection After Lung Transplantation. ISHLT Annual Meeting. San Diego, CA 4/14.
241. L.C. Reardon, J.C. Alejos, A.A. Nsair, R.M. Biniwale, M.C. Deng, B. Reemtsen, A. Ardehali, E.C. Depasquale. Post Heart Transplant (HT) Survival in Pediatric Patients with Left Ventricular and Biventricular Assist Devices (LVAD/BIVAD): UNOS Registry Analysis. ISHLT Annual Meeting. San Diego, CA 4/14.
242. A.-M. Hoffmann-Vold , R. Huynh, E. Volkmann, S. Palchevskiy, Ø. Midtvedt, T. Garen, A. Der Hovanessian, S. Weigt, M. Fishbein, A. Ardehali, D. Ross, R. Sagggar, J. Lynch, P. Aukrust, T. Ueland, R. Elashoff, Ø. Molberg, J. Belperio. Augmented Concentrations of CX3CL1 are Associated with Progressive Interstitial Lung Disease in Systemic Sclerosis. EULAR16-4406
243. L.C. Reardon, A. Nsair, M.C. Deng, A. Ardehali, J. Alejos, E.C. DePasquale. Influence of Chronic Kidney Disease (CKD) in Outcomes Post Heart Transplant (HT) in Pediatric Recipients. ISHLT Annual Meeting. Nice, France 4/15.

244. A. Ardehali, C. Eisenring, J. Kobashigawa. Ex-Vivo Heart Perfusion Using the Organ Care System Reduces the Donor Heart Cold Ischemia Time. ISHLT Annual Meeting. Nice, France 4/15.
245. K.J. Lyons, K.A. Pandya, A. Nsair, A.S. Baas, M. Cadeiras, D. Cruz, L.C. Reardon, A. Ardehali, and others. Outcomes of Alcohol Cardiomyopathy Post Heart Transplantation. ISHLT Annual Meeting. Nice, France 4/15.
246. E.C. DePasquale, L. Reardon, A. Nsair, M. Deng, A. Ardehali. Cardiac Retransplantation: Third Time's the Charm? ISHLT Annual Meeting. Nice, France 4/15.
247. K. Pandya, K. Lyons, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, L. Reardon, M. Deng, and others. Outcomes of Heart Transplantation in Adults With Congenital Heart Disease: UNOS Registry Analysis. ISHLT Annual Meeting. Nice, France 4/15.
248. E.C. DePasquale, K. Pandya, K. Lyons, L. Reardon, A. Nsair, M. Deng, A. Ardehali. Outcomes of Heart Transplantation in Adults With Amyloidosis: UNOS Registry Analysis. ISHLT Annual Meeting. Nice, France 4/15.
249. B.G. Tran, E. Depasquale, J. Meltzer, A. Ardehali, D. Cruz, M. Deng, R. Shemin, A. Nsair. Temporary Extracorporeal Membrane: Oxygenation: Ten-Year Experience at a Cardiac Transplant Center. ISHLT Annual Meeting. Nice, France 4/15.
250. K. Pandya, K. Lyons, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, L. Reardon, M. Deng, and others. Cardiac Retransplantation: How Far Have We Come? ISHLT Annual Meeting. Nice, France 4/15.
251. A. Iyengar, E.C. DePasquale, D. Ross, A. Ardehali. Contemporary Redo Lung Transplantation: An Analysis of the UNOS Database. ISHLT Annual Meeting. Nice, France 4/15.
252. G. Warnecke, D. Van Raeonck, M. Smith, J. Kukreja, G. Loor, F. Rea, G. Massard, F. De Robertis, and others. The Organ Care System (OCS™) Lung INSPIRE International Trial Results. ISHLT Annual Meeting. Nice, France 4/15.
253. J. Lan, M. Hickey, M. Cadeiras, E.C. Depasquale, N. Halnon, A. Baas, G. Perens, A. Nsair, and others. Complement-Fixing Donor-Specific HLA Antibodies Detected By Novel C3d Assay Are Associated With Antibody Mediated Rejection in Heart Transplant Recipients. ISHLT Annual Meeting. Nice, France 4/15.
254. K. Pandya, J. Zhang, M. Hickey, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, L. Reardon, and others. Influence of HLA Mismatch on Outcomes After Heart

- Transplantation: UNOS Registry Data. ISHLT Annual Meeting. Nice, France 4/15.
255. Biniwale R, Ross D, Iyengar A, Kwon OJ, Hunter C, Aboulhosn J, Gjertson D, Ardehali A. Lung transplantation and concomitant cardiac surgery: Is it justified? Annual Meeting of American Association for Thoracic Surgery. Toronto, Canada, 5/15.
 256. G. Warnecke, D. Van Raemdonck, J. Kukreja, M. Smith, G. Loor, F. Rea, G. Massard, F. De Robertis, J. Nagendran, J. Moradiellos, K. Dhital, C. Knosalla, C. Bermudez, S. Tsui, J. Madsen, I. Wang, K. McCurry, T. Deuse, P. Thomas, W. Somemer, B. Weigmann, C. Khun, I. Tudorache, M. Avsar, M. Schiavon, N. Santelmo, A. Olland, P. Falcoz, V. Varela, M. Hertz, A. Simon, H. Reichensperner, A. Haverich, A. Ardehali. Mid and Long –Term Clinical Results of OCS lung INSPIRE International Trial. ISHLT Annual Meeting. Washington D.C. 4/16.
 257. A. Iyengar, C. Eisenring, L. Reardon, A. Nsair, M. Deng, A. Ardehali, E. DePasquale. Influence of the MELD-XI (Model of End –Stage Liver Disease Excluding INR) on Heart Transplant Outcomes. ISHLT Annual Meeting. Washington, D.C. 4/16.
 258. E.C. DePasquale, M. Deng, A. Ardehali, D Jacoby. Outcomes of Heart Transplantation in Adults with Hypertrophic Cardiomyopathy (HCM): UNOS Registry Analysis. ISHLT Annual Meeting. Washington, D.C. 4/16.
 259. E.C. DePasquale, A. Salimbanon, A. Chang, E. Howell, A. Nsair, M. Deng, A. Ardehali. Competing Outcomes of Heart Transplantation in Adults Bridged with Total Artificial Heart (TAH): UNOS Registry Analysis. ISHLT Annual Meeting. Washington D.C 4/16.
 260. G. Loor, G. Warnecke, M. Smith, J Kukreja, A. Ardehali, J. Moradiellos, A. Varela, J. Maden, M. Hertz, D. Van Raemdonck. The OCS Lung EXPAND International Trial Interim Results. ISHLT Annual Meeting. Washington, D.C. 4/16.
 261. A. Ardehali, G. Warnecke, D. Van Raemdonck, G. Loor, J. Kukreja, M. Smith, F. Rea, G. Massard, F. De Robertis, J. Nagendran, J. Moradiellos, K. Dhital, C. Knosalla, C. Bermudez, S. Tsui, I. Wang, K, McCurry, T. Deuse, P. Thomas, W. Sommer, B. Wiegmann, I. Tudorache. C. Khun, M. Avsar, M. Schiavon, N. Santelmo, A. Olland, P. Falcoz, A. Varela, A. Simon, H. Reichensperner, A. Haverich, J. Madsen, M Hertz. Impact of OCS Lung Portable EVLP on Pulmonary Function and Bronchiolitis Obliterans in Standard Lung Transplant

- Recipients-Prospective Evidence from the OCS Lung INSPIRE Trial Patients. ISHLT Annual Meeting. Washington D.C. 4/16.
262. E.C. DePasquale, A. Salimbangon, E. Howell, A. Chang, A. Nsair, A. Ardehali. Biventricular Bridge to Transplant: Total Artificial Heart (TAH) vs Thoratec Parcorporeal VAD's (PVAD'S) Outcomes Post Heart Transplant. ISHLT Annual Meeting. Washington, D.C. 4/16.
 263. E.C. DePasquale, A. Iyengar, A. Nsair, K. Pandya, M. Deng, A. Ardehali. Outcomes of Heart Transplantation in Adults with Sarcoidosis: UNOS Registry Analysis. ISHLT Annual Meeting. Washington, D.C. 4/16.
 264. M. Bakir, N. Jackson, E. Chang, D. Henriquez, C. Tseng, C. Starling, T. Khuu, D. Cruz, E. DePasquale, A. Ardehali, J. Zhang, J. Schaenman, B. Kubak, M. Kwon, A. Ardehali, E. Reed, M. Deng, M. Cadeiras. Steps towards Personalization of Clinical Care in Era of Precision Medicine. Time Dependent Immune Phenomapping in Heart Transplantation and Emergence of Anti- HLA Class I and II Antibodies. ISHLT Annual Meeting. Washington, D. C. 4/16.
 265. A. Iyengar, C. Eisenring, A. Nsair, A. Deng, L. Reardon, A. Ardehali, E. DePasquale. Outcomes in Patients Older than 65 Years of Age Post Heart (HT) & Heart-Kidney Transplant (HKT). ISHLT Annual Meeting. Washington, D.C. 4/16.
 266. A. Iyengar, O. Kwon, A. Bhutani, D. Ross, A. Ardehali. Lung Transplantation in Septuagenarians. ISHLT Annual Meeting. Washington, D.C. 4/16.
 267. A. Iyengar, C. Eisenring, E. DePasquale, D. Ross, A. Ardehali. Combined Lung-Liver Transplantation: And Analysis of the UNOS Database. ISHLT Annual Meeting. Washington, D.C. 4/16.
 268. A. Iyengar, C. Eisenring, E. DePasquale, D. Ross, A. Ardehali. ECMO as a Bridge to Lung Transplantation: An Analysis of the UNOS Database. ISHLT Annual Meeting. Washington, D.C. 4/16.
 269. A. Iyengar, O. Kwon, A. Bhutani, D. Ross, A. Ardehali. Lung Transplantation in the LAS Era: Long Term Analysis. ISHLT Annual Meeting. Washington, D.C. 4/16.
 270. S.S. Weigt, X. Wang, V. Palchevskiy, N. Patel, A. DerHovanessian, M.Y. Shino, D. Sayah, A. L. Gregson, J.P. Lynch III, R. Saggari, D.J. Ross, A. Ardehali, D. Elashoff, J.A. Belperio. Gene Expression Profiling of Bronchoalveolar Lavage Cells during Aspergillus Colonization of the Lung Allograft. ISHLT Annual Meeting. Washington, D.C. 4/16.

271. A. Iyengar, A. Bhutani, O. Kwon, D. Ross, A. Ardehali. Primary Graft Dysfunction in Lung Transplantation: A Detailed Predictive Model. ISHLT Annual Meeting. Washington, D.C. 4/16.
272. A. Salimbangon, J.A. Cowger, D. Vucicevic, L. Honoris, A. Iyengar, S. Shah, E. Moreno, A. Chang, L. Reardon, K. Pandya, M.C. Deng, A. Ardehali, E.C. DePasquale. Trends in 1A Listing Exceptions in Heart Transplant Recipients Bridged by Left Ventricular Assist Device Type. ISHLT Annual Meeting. San Diego, CA. 4/17.
273. E.C. DePasquale, J.A. Cowger, L. honoris, D. Vucicevic, S. Shah, A. Iyengar, A. Salimbangon, E. Moreno, A. Chang, L. Reardon, K. Pandya, M. Deng, A. Ardehali. Trends in 1A Listing Exceptions in Heart Transplant Recipients Bridged with Mechanical Circulatory Support. ISHLT Annual Meeting. San Diego, CA. 4/17.
274. M. Bakir, N. Jackson, S. Han, C. Tseng, E. Chang, T. Khuu, A. Bui, Q. Zhang, E. Reed, D. Liem, B. Kubak, J. Schaenman, A. Ardehali, R. Ardehali, A. Baas, A. Nsair, D. Cruz, M. Kwon, E. DePasquale, M. Deng, M. Cadeiras. Cluster Analysis and Dynamic Phenomapping to Guide Clinical Management After Heart Transplantation. ISHLT Annual Meeting. San Diego, CA. 4/17.
275. D. Vucicevic, L. Honoris, M. Moore, L. Sweet, A. Salimbangon, A. Chang, E. Moreno, K. Pandya, A. Iyengar, S. Shah, B. Kubak, A. Ardehali, M. Deng, E. DePasquale. Treatment with IV Antibiotics Immediately Pre-Transplant is Associated with Increased Mortality in Heart Transplant Recipients. ISHLT Annual Meeting. San Diego, CA. 4/17.
276. D. Vucicevic, L. Honoris, A. Salimbangon, A. Chang, E. Moreno, K. Pandya, A. Iyengar, S. Shah, M. Moore, L. Sweet, M. Deng, A. Ardehali, E. DePasquale. More Inactive Time on Heart Transplant List Results in Increased Post Transplant Mortality. ISHLT Annual Meeting. San Diego, CA. 4/17.
277. A. Iyengar, D. Vucicevic, E. Adams, C. Eisenring, L. Reardon, M. Deng, A. Ardehali, E. DePasquale. Center for Disease Control High Risk Donor Use in Heart Transplantation: Current Trends. ISHLT Annual Meeting. San Diego, CA. 4/17.
278. S. Shah, D. Cruz, M. Deng, A. Ardehali, E.C. DePasquale. Assessing Risk of Primary Graft Dysfunction in Heart Transplantation. ISHLT Annual Meeting. San Diego, CA. 4/17.

279. D. Vucicevic, L. Honoris, A. Salimbangon, A. Chang, E. Moreno, M. Moore, L. Sweet, S. Shah, A. Iyengar, K. Pandya, A. Ardehali, M. Deng, E. DePasquale. Trends in Combined Heart-Kidney Transplantation and Impact on Patient Survival. ISHLT Annual Meeting. San Diego, CA. 4/17.
280. N. Harati, A. Iyengar, E. Adams, C. Eisenring, L. Reardon, M. Deng, A. Ardehali, E. Depasquale. Socioeconomic Status and Heart Transplantation. ISHLT Annual Meeting. San Diego, CA. 4/17.
281. A. Iyengar, E. Adams, C. Eisenring, N. Satou, L. Reardon, M. Deng, R.J. Shemin, A. Ardehali, E. Depasquale. The In-Hospital Cost of Heart Transplantation. ISHLT Annual Meeting. San Diego, CA. 4/17.
282. D. Vucicevic, L. Honoris, A. Chang, E. Moreno, A. Salimbangon, M. Moore, L. Sweet, S. Shah, A. Iyengar, K. Pandya, A. Ardehali, M. Deng, E. DePasquale. The Use of Intra-Aortic Balloon Pump Pre-Transplant Is Associated with Worse Outcomes in Heart Transplant Recipients. ISHLT Annual Meeting. San Diego, CA. 4/17.
283. A. Iyengar, E. Adams, N. Harati, C. Eisenring, D. Ross, E. DePasquale, A. Ardehali. Influence of Ischemic Time on Post Lung Transplant Outcomes. ISHLT Annual Meeting. San Diego, CA. 4/17.
284. A. Iyengar, N. Harati, E.D. Adams, C. Eisenring, L. Reardon, M. Deng, A. Ardehali, E. DePasquale. Heart Transplantation in Prostrate Cancer Patients. ISHLT Annual Meeting. San Diego, CA. 4/17.
285. A. Iyengar, O. Kwon, N. Harati, C. Eisenring, E. DePasquale, D. Ross, A. Ardehali. Does PGD3 at 0-48 Hours After Lung Transplantation Matter? ISHLT Annual Meeting. San Diego, CA. 4/17.
286. M.Y. Kamath, N. Bellam, M. Moore, A. Salimbangon, A. Chang, A. Nsair, M. Cadeiras, M. Kwon, A. Ardehali, E. Depasquale. Extracorporeal Membrane Oxygenation to Transplant Survival: Past, Present, and Future. ISHLT Annual Meeting. Nice, France. 4/18
287. A. Iyengar, M. Caceres Polo, O. Kwon, E. Adams, L. Reardon, J. Schaeffer, M. Kwon, A. Ardehali, E. DePasquale. Elevated Panel Reactive Antibodies in Patients Bridged to heart Transplantation with Ventricular Assist Devices. ISHLT Annual Meeting. Nice, France. 4/18
288. T. Khuu, M. Kamath, J. Smith, J. Fuentes, M. Cadeiras, A. Nsair, A. Baas, L. Sweet, S. Frascilla, D. Cruz, M. Moore, M.C. Deng, A. Ardehali, E.C.

- DePasquale. Optimizing Immunosuppression: Steroid Weaning Strategies in Heart Transplant. ISHLT Annual Meeting. Nice, France. 4/18
289. M.Y. Kamath, J. Wilson, N. Bassi, S. Frascilla, A. Iyengar, M. Moore, S. Shah, D. Vucicevic, K. Pandya, M. Deng, A. Ardehali, E. Depasquale. Heart Transplant Outcomes in Patients Listed for Kidney Transplant. ISHLT Annual Meeting. Nice, France. 4/18
290. N. Bellman, M. Kamath, E.C. Depasquale, J.G. Smith, J. Fuentes, R. Ardehali, A.S. Baas, M. Cadeiras, M. Deng, M.H. Kwon, A. Ardehali, A. Nsair, T. Khuu. Direct Acting Oral Anticoagulant Utilization, Safety and Efficiency in Heart Transplant. ISHLT Annual Meeting. Nice, France. 4/18
291. M.Y. Kamath, A. Salimbangon, A. Chang, E. Moreno, M. Cadeiras, M. Deng, T. Khuu, A. Nsair, A. Ardehali, M. Kwon, E. Depasquale. LVAD Patients with CKD: Are Two Organs Better than One? ISHLT Annual Meeting. Nice, France. 4/18
292. G. Loor, G. Warnecke, M. Villavicencio, M. Smith, J. Kukreja, A. Ardehali, M. Hartwig, M. Daneshmand, M. Hertz, A. Haverich, J. Madsen, D. Van Raemdonck. Results of the OCS Lung EXPAND International Trial Using Portable Normothermic OCS Lung Perfusion System (OCS) to Recruit and Evaluate Extended Criteria Donor (ECD) Lungs. ISHLT Annual Meeting. Nice, France. 4/18
293. G. Warnecke, D. Van Raemdonck, J. Kukreja, M. Smith, G. Loor, F. Rea, G. Massard, F. De Robertis, J. Nagendran, J. Moradiellos, K. Dhital, C. Knosalla, C. Bermudez, S. Tsui, J. Madsen, I. Wang, K. McCurry, T. Deuse, P. Thomas, I. Tudorache, B. Wiegmann, M. Schiavon, F. Calabrese, N. Santelmo, A. Olland, P. Falcoz, A. Varela, M. Hertz, A. Simon, H. Resichenspurner, A. Haverich, A. Ardehali. Negative Impact of Ischemia on Short and Long Term Outcomes in Standard Criteria Double Lung Transplants Prospective Evidence from the OCS Lung INSPIRE International Trial Results. ISHLT Annual Meeting. Nice, France. 4/18
294. M. Caceres Polo, A. Iyengar, O. Kwon, J. Schaenman, R. Biniwale, D. Ross, E. DePasquale, A. Ardehali. Outcomes of ECMO Bridge to Lung Transplantation are Dependent on Age. ISHLT Annual Meeting. Nice, France. 4/18
295. A. Iyengar, M. Caceres Polo, E. Aguayo, J. Schaenman, R. Biniwale, D. Ross, E. DePasquale, A. Ardehali. Early Survival after Lung Transplantation is Improving in Patients over Age 65. ISHLT Annual Meeting. Nice, France. 4/18
296. S.M. Lari, M. Caceres Polo, A. Iyengar, D.J. Ross, S. Weight, R. Saggari, D. Sayah, M. Shino, A. Der Hovanessian, J.P. Lynch III, J. Belperio, A. Ardehali.

- Extra-corporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplantation: Outcomes in the Current Era. ISHLT Annual Meeting. Nice, France. 4/18
297. K.L. Bailey , A. Iyengar, O. Kwon, M. Caceras, C. Eisenring, D. Ross, A. Ardehali. Ambulatory Status Improves Outcomes in Patients Bridged to Lung Transplantation with ECMO. ISHLT Annual Meeting. Nice, France. 4/18
 298. D. Vucicevic, A. Chang, A. Salimbangaon, M. Kamath, E. Moreno, A. Iyengar, S. Shah, M. Cadeiras, A. Ardehali, M. Deng, E. DePasquale. Impaired Kidney Function and Impact on Survival After Left Ventricular Assist Device Implantation as a Bridge to Transplantation. ISHLT Annual Meeting. Nice, France. 4/18
 299. T. Khuu, E. DePasquale, A. Salimbangon, A. Chang, E. Moreno, D. Rourke, J. Creaser, E. Vandenbogaart, M.H. Kwon, A. Ardehali, A. Nsair. Reduced Readmissions with Enoxaparin Bridging for Subtherapeutic INR in MCS. ISHLT Annual Meeting. Nice, France. 4/18
 300. A. Iyengar, M. Caceres Polo, B. Sowell, O. Kwon, E. Adams, L. Reardon, A. Ardehali, E. DePasquale. Recipient Working Status is Independently Associated with Outcomes in Heart Transplantation. ISHLT Annual Meeting. Nice, France. 4/18
 301. A. Chang, A. Nsair, M. Kwon, M. Kamath, A. Salimbangon, D. Vucicivec, M. Cadeiras, M. Deng, E. Moreno, N. Bellam, A. Iyengar, S. Shah, A. Ardehali, E. Depasquale. Survival Post Heart Transplant by Listing Strategy. ISHLT Annual Meeting. Nice, France. 4/18
 302. A. Iyengar, A. Goel, M. Caceres Polo, O. Kwon, C. Eisenring, R. Biniwale, E. DePasquale, A. Ardehali. Intellectual Disability and Pediatric Lung Transplantation. ISHLT Annual Meeting. Nice, France. 4/18
 303. R. Meguerdijian, A. Chang, E. Moreno, A. Salimbangon, M. Kamath, T. Khuu, M. Kwon, M. Moore, A. Nsair, K. Pandya, D. Vucicevic, A. Ardehali, M.C. Deng, E.C. DePasquale. Improving Utility of MELD-XI Prognostication in Heart Transplant. ISHLT Annual Meeting. Nice, France. 4/18
 304. D. Vucicevic, A. Salimbangon, A. Chang, E. Moreno, M. Kamath, A. Iyengar, S. Shah, M. Deng, A. Ardehali, M. Cadeiras, E. DePasquale. Redo Heart Transplantation: The Comparison of Survival Based on the Time Interval Between Transplants. ISHLT Annual Meeting. Nice, France. 4/18

305. D. Vucicevic, A. Chang, A. Salimbangon, E. Moreno, M. Kamath, S. Shah, A. Iyengar, M. Cadeiras, A. Ardehali, M. Deng, E. DePasquale. The Comparison of Survival in Patients with Redo Heart Transplantation by Era. ISHLT Annual Meeting. Nice, France. 4/18
306. M.Y. Kamath, N. Bassi, J. Wilson, N. Bellam, T. Khuu, A. Iyengar, D. Vucicevic, M. Deng, A. Ardehali, E. DePasquale. Survival in Re-Do Heart Transplant: Does Dual Organ Allocation Make a Difference? ISHLT Annual Meeting. Nice, France. 4/18
307. A. Khurshudyan, A. Iyengar, O. Kwon, M. Caceres, C. Eisenring, D. Ross, A. Ardehali. Bronchiolitis Obliterans Syndrome in Lung Transplantation: A Predictive Model. ISHLT Annual Meeting. Nice, France. 4/18
308. A. Iyengar, A. Khurshudyan, O. Kwon, M. Caceres Polo, C. Eisenring, R. Biniwale, D. Ross, A. Ardehali. Cardiopulmonary Bypass Use Does Not Affect Outcomes in Single Lung Transplantation. ISHLT Annual Meeting. Nice, France. 4/18
309. A. Iyengar, M. Caceres Polo, O. Kwon, N. Faiq, R. Biniwale, E. DePasquale, A. Ardehali. Recipient Working Status is Independently Associated with Outcomes in Lung Transplantation. ISHLT Annual Meeting. 4/18
310. A. Iyengar, M. Caceres Polo, O. Kwon, J. Schaenman, R. Biniwale, D. Ross, E. DePasquale, A. Ardehali. Single vs. Double Lung Transplantation in Patients over Age 65. ISHLT Annual Meeting. Nice, France. 4/18
311. A. Ardehali, D. Van Raemdonck, J. Kukreja, M. Smith, G. Loor, F. Rea, G. Massard, F. De Robertis, J. Nagendran, J. Moradiellos, K. Dhital, C. Knosalla, C. Bermudez, S. Tsui, J. Madsen, I. Wang, K. McCurry, T. Deuse, P. Thomas, I. Tudorache, B. Wiegmann, M. Schiavon, F. Calabrese, N. Santelmo, A. Olland, P. Falcoz, A. Varela, H. Hertz, A. Simon, H. Resichenspurner, A. Haverich, G. Warnecke. Negative Impact of Primary Graft Dysfunction Grade 3 within the Initial 72 Hours on Short and Long Term Clinical Outcomes in Standard Criteria Double Lung Transplants: Prospective Evidence from the OCS Lung INSPIRE International Trial Results. ISHLT Annual Meeting. Nice, France. 4/18

Updated 04/2018